👪

Inheritance

2

X-linked Dominant HP:0001423

Heterozygous truncating MED12 variants on the X chromosome produce disease in females. Whether severe male loss-of-function genotypes are embryonically lethal is an inference drawn from the exclusively female ascertainment, not a measured penetrance.

X-linked dominant inheritance

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT BACKGROUND Human Clinical

"Hardikar syndrome (HS, OMIM #301068) is an X-linked dominant disorder characterized by cleft lip/palate, pigmentary retinopathy, aortic coarctation, intestinal malrotation, hepatobiliary disease and genitourinary malformations with preserved neurocognition"

States the inheritance mode and the core phenotype. Graded BACKGROUND because it is the paper's introductory restatement of the two earlier clinical reports, not a result of the cohort described in it.

De Novo Occurrence HP:0003745

Most molecularly characterized cases arose de novo. Mosaicism has been suspected in at least one individual, so a zero recurrence risk should not be assumed without parental testing.

Sporadic

Show evidence (1 reference)

PMID:33244166 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We additionally report the discovery of de novo pathogenic nonsense and frameshift variants in MED12 in these seven individuals and evidence of extremely skewed XCI in all patients with informative testing."

Establishes de novo occurrence in the gene-discovery cohort.

?

Discussions and Knowledge Gaps

3

Does MED12 promote or inhibit Hedgehog signaling, and does the answer depend on whether the cell is ciliated?

CONTROVERSY OPEN hardikar_med12_hedgehog_direction

Attached to

pathophysiology#Impaired Hedgehog Pathway Activation

The 2024 Hardikar cohort found that MED12 knockdown abolishes agonist-induced GLI1 induction, which makes MED12 a positive regulator of Hedgehog signaling. Earlier work reported the opposite, that MED12 inhibits Hedgehog, and the authors flag the contradiction themselves rather than leaving it implicit. Their proposed explanations are that their experiments were performed in serum-free conditions in which cells are ciliated, and that MED12 may have a cilium-independent effect on Hedgehog that the earlier studies measured and theirs did not. This is not only an external disagreement. dismech already encodes the inhibitory direction for a different MED12 allele: the FG syndrome entry carries a pathophysiology node for derepression of GLI3-dependent Sonic Hedgehog target transcription, which asserts that MED12 normally restrains Hedgehog output. Both entries may be right, because the alleles differ - FG syndrome is the recurrent p.R961W missense that impairs MED12-CDK8 association, while this entry's alleles are truncating - but the two directions should not be asserted side by side in the knowledge base without the tension being recorded. Resolving it bears on whether the two arms of the MED12 series share a mechanism or merely a gene.

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT In Vitro

"This contrasts with our data, which suggests that MED12 promotes hedgehog signaling."

The authors' statement of the disagreement, immediately after noting the prior reports that MED12 inhibits Hedgehog signaling.

Which cell types lose primary cilia, Hedgehog output or YAP/TEAD output in each affected organ, and when during development?

KNOWLEDGE GAP OPEN hardikar_organ_specific_lesion

Attached to

pathophysiology#Disrupted Developmental Organogenesis

Every molecular measurement behind this entry's mechanism was made in a retinal pigment epithelial cell line by siRNA knockdown. That establishes that MED12 loss reduces ciliation and Hedgehog and YAP output in a cell, and it does not establish which of the malformed organs each defect accounts for, nor whether the relevant window is the same for the biliary tree, the palate, the retina and the aorta. There is no patient-cell atlas for this syndrome, and no patient-derived line has been profiled. The authors themselves name the experiment that would close this: interrogation of ciliogenesis and YAP signaling, with unbiased transcriptomics and proteomics, in fibroblast lines from unaffected relatives, individuals with Hardikar syndrome, and individuals with MED12-related intellectual disability.

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT In Vitro

"To evaluate a role for MED12 in ciliogenesis, retinal pigment epithelial (RPE) cells, an established cell model for the study of ciliopathy-spectrum disease, were serum starved for 24 hours to promote ciliogenesis or were grown in complete medium (control) and MED12 expression was evaluated by..."

Names the single cell system the mechanism rests on, which is what makes the organ-level assignment a gap.

In which affected organs does X-inactivation skewing favour the intact MED12 allele, and does the direction of skewing explain why some individuals present with liver disease alone?

KNOWLEDGE GAP OPEN hardikar_xci_tissue_distribution

Attached to

pathophysiology#Extremely Skewed X-Chromosome Inactivation

Skewed X-inactivation was found in every informatively tested individual, so it is a real and consistent feature rather than an incidental one. What it cannot do, measured in blood, is say which allele is active in liver, retina, palate or aorta. This matters for a specific clinical observation: at least one reported infant presented with severe hepatobiliary disease and few other anomalies, which organ-specific skewing is an obvious candidate to explain and which nothing currently tests. Settling it needs allele-specific expression in affected tissue, which for most of these organs means post-mortem or explant material.

Show evidence (1 reference)

PMID:42510827 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"Unlike most previously reported cases, the predominant and early manifestation in our case was severe hepatobiliary disease with limited additional anomalies, suggesting possible phenotypic variability within the MED12-related Hardikar syndrome spectrum."

The organ-restricted presentation this gap is about. Indirect because the individual's variant remained of uncertain significance and because the report does not test X-inactivation as the explanation.

⚙

Pathophysiology

10

MED12 Truncating Loss of Function

Mechanism confidence: Established

De novo heterozygous nonsense, frameshift or splice-site variants in MED12 remove functional protein from one X-linked allele. This allele class is what distinguishes Hardikar syndrome from the rest of the MED12 series: the hemizygous male syndromes arise from recurrent missense alleles, and somatic missense variants in the same gene drive uterine leiomyoma.

MED12 hgnc:11957

Genetic context variant_origin: DE_NOVO zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Nonsense and frameshift alleles predicted to trigger nonsense-mediated decay, plus splice-site alleles added by the 2024 cohort.

Downstream

Reduced MED12 Dosage in the Mediator Kinase Module A truncating allele removes functional MED12 from the dissociable kinase module of Mediator.

Show evidence (3 references)

PMID:33244166 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We propose a fifth, female-specific phenotype for MED12, and suggest that nonsense and frameshift loss-of-function MED12 variants in females cause HS."

The gene-discovery conclusion: truncating loss-of-function MED12 alleles in females cause this syndrome, as a distinct entity within the MED12 series.

PMID:39045790 SUPPORT DIRECT BACKGROUND Human Clinical

"HS is specifically associated with de novo nonsense and frameshift MED12 variants"

Confirms the allele class is specific to this disorder within the MED12 series.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We report novel phenotypes associated with HS, including cardiomyopathy, arrhythmia, and vascular anomalies, and expand the molecular landscape of HS to include splice site variants."

Extends the allele class from nonsense and frameshift to splice-site variants.

Extremely Skewed X-Chromosome Inactivation

Mechanism confidence: Established

All informatively tested individuals in the gene-discovery series showed extremely skewed X-chromosome inactivation. This is measured in accessible tissue, usually blood, and so constrains but does not establish which allele is expressed in liver, retina or any other affected organ; it is recorded here as a modifier of expression rather than as the initiating lesion.

MED12 hgnc:11957

Downstream

Reduced MED12 Dosage in the Mediator Kinase Module Skewing determines what fraction of cells in a given tissue express the intact allele, and so modulates effective MED12 dosage per organ. Which direction the skewing runs in each affected organ is not established.

Show evidence (1 reference)

PMID:33244166 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We additionally report the discovery of de novo pathogenic nonsense and frameshift variants in MED12 in these seven individuals and evidence of extremely skewed XCI in all patients with informative testing."

Reports the skewed X-inactivation finding in every informatively tested patient.

Reduced MED12 Dosage in the Mediator Kinase Module

Mechanism confidence: Established

MED12 is the scaffold subunit of the four-part Mediator kinase module (MED12, MED13, CCNC, CDK8), a dissociable regulatory cap on core Mediator. Reduced MED12 lowers the module's contribution to transcriptional regulation, including MED12's own interactions with chromatin and transcription factors.

MED12 hgnc:11957

transcription by RNA polymerase II GO:0006366 ↕ DYSREGULATED

transcription coregulator activity GO:0003712 ↓ DECREASED

Downstream

Impaired Primary Ciliogenesis MED12 is required to sustain primary ciliation; its loss reduces the proportion of ciliated cells.

Impaired YAP-TEAD Transcriptional Output MED12 loss lowers YAP/TEAD-driven transcription without reducing YAP itself.

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT BACKGROUND Other

"MED12 interacts with chromatin and transcription factors to modulate chromatin architecture and transcriptional activity"

States the molecular function lost when MED12 dosage falls, which is what the GO:0003712 binding records. Graded OTHER with quote_role BACKGROUND because the sentence is the paper's introductory summary of three prior studies rather than its own result.

Impaired Primary Ciliogenesis

Mechanism confidence: Established

MED12 expression rises about two-fold in cells induced to form primary cilia and falls by about half during ciliary disassembly, and its knockdown reduces the ciliated fraction without shortening cilia. The reduction is not explained by cells cycling faster, since knockdown also halves proliferation. This places Hardikar syndrome partly within ciliopathy-spectrum biology, which is where its retinopathy, biliary dysgenesis and fibrotic liver disease overlap clinically.

retinal pigment epithelial cell CL:0002586

non-motile cilium assembly GO:1905515 ↓ DECREASED

Downstream

Impaired Hedgehog Pathway Activation The primary cilium houses the Hedgehog pathway, and an intact cilium is required for the response to a Smoothened agonist. Knockdown of the independent ciliogenesis factor TTBK2 reduced ciliation and abolished the same response, so the cilium rather than MED12 itself is the proximate requirement.

Disrupted Developmental Organogenesis Reduced ciliary signaling during development is the proposed route to the ciliopathy-like features: retinopathy, biliary dysgenesis and fibrotic liver disease. Which cells lose cilia in which organ, and when, is not demonstrated.

Show evidence (3 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Serum-starved RPE cells undergoing ciliogenesis had a 2-fold increase in MED12 expression compared to cells treated with complete medium"

MED12 is upregulated when cells build primary cilia, supporting a role in ciliogenesis.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT In Vitro

"RPE cells treated with serum and undergoing ciliary disassembly had a 50% reduction in MED12 expression, supporting a role for MED12 in the inhibition of ciliary disassembly"

The reciprocal observation during ciliary disassembly.

PMID:39045790 SUPPORT INDIRECT PRIMARY RESULT In Vitro

"Cells transfected with MED12 siRNA had a ~50% reduction in cell proliferation, suggesting that the decrease in percent ciliated cells is not due to increased proliferation"

Excludes the main alternative explanation for a lower ciliated fraction. Indirect because it supports the claim by ruling out a confounder rather than by measuring ciliogenesis.

Impaired Hedgehog Pathway Activation

Mechanism confidence: Established

MED12-deficient cells fail to induce GLI1 in response to the Smoothened agonist SAG, which control cells do robustly. The direction of this effect is the opposite of what earlier work on MED12 and Hedgehog reported, and the discrepancy is unresolved; see discussion hardikar_med12_hedgehog_direction.

retinal pigment epithelial cell CL:0002586

smoothened signaling pathway GO:0007224 ↓ DECREASED

Downstream

Disrupted Developmental Organogenesis Hedgehog signaling patterns many of the structures malformed in this syndrome. The organ-by-organ assignment is inferred from pathway biology rather than demonstrated in patient tissue.

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Cells treated with control siRNA had a robust induction of GLI1 expression in response to SAG; MED12 deficiency abrogated the response"

Direct measurement of the Hedgehog signaling defect, read out as loss of agonist-induced GLI1 induction.

Impaired YAP-TEAD Transcriptional Output

Mechanism confidence: Established

MED12 knockdown lowers expression of the YAP target genes CTGF and CYR61 and reduces TEAD-responsive reporter activity. The effect is not explained by less YAP protein: YAP mRNA rises and phosphorylated YAP falls, which the authors read as attempted compensation. Their model is that MED12 directly enhances YAP/TEAD-mediated transcription.

retinal pigment epithelial cell CL:0002586

YAP/TEAD-mediated gene transcription GO:0006357 ↓ DECREASED

TEAD-YAP complex GO:0140552

Downstream

Disrupted Developmental Organogenesis YAP signaling has established roles in orofacial clefting and angiogenesis, both features of this syndrome.

Cardiac and Vascular Wall Vulnerability Proposed, not demonstrated. The authors note that YAP and TGF-beta signaling modulate angiogenesis and cardiomyopathy, and separately that heart disease in this syndrome may arise independently of ciliary and YAP effects. Recorded as the leading hypothesis for the cardiovascular arm.

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT In Vitro

"These data are most consistent with a model in which MED12 directly enhances YAP/TEAD-mediated gene transcription."

The authors' mechanistic reading of their own YAP target-gene and reporter data, which is what this node asserts.

Disrupted Developmental Organogenesis

Mechanism confidence: Provisional

Reduced ciliary, Hedgehog and YAP/TEAD output during embryogenesis is the proposed common cause of the structural malformations. The lesion responsible for each individual human feature has not been demonstrated, and the malformations are established prenatally, so they are persistent rather than progressive after birth.

digestive tract morphogenesis GO:0048546 ⚠ ABNORMAL

Downstream

Biliary Dysgenesis Maldevelopment of the intra- and extrahepatic biliary tree.

Cleft lip

Cleft palate

Pigmentary retinopathy

Intestinal malrotation

Coarctation of aorta

Hydronephrosis

Vesicoureteral reflux

Ectopic ureteral orifice

Hearing impairment

Preauricular pit

Preauricular skin tag

Branchial anomaly Preauricular pits and tags and branchial cleft anomalies are all first and second pharyngeal arch derivatives, which is consistent with their being the most frequent feature in the cohort.

Vaginal atresia

Meckel diverticulum A persistent omphalomesenteric duct remnant, so a midgut developmental failure alongside the malrotation.

Congenital diaphragmatic hernia

Scoliosis

Short stature Reduced growth is recorded in about a third of the cohort. Whether it is a primary consequence of the transcriptional defect or secondary to the cholestatic and feeding burden is not established.

Constipation Plausibly downstream of the enteric malformations rather than a separate lesion; the source scores it as a clinical finding without assigning a mechanism.

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT In Vitro

"We propose a model in which loss of MED12 interferes with the transcription of genes critical for ciliogenesis and also impairs YAP pathway activation, leading to the severe developmental abnormalities characteristic of HS"

The proposed mechanism linking the measured molecular defects to the malformation pattern. Stated by its authors as a model, which is why this node is PROVISIONAL.

Biliary Dysgenesis

Mechanism confidence: Established

Maldevelopment of the biliary tree is the recurrent hepatobiliary lesion, reported as biliary atresia, bile-duct paucity, absent gallbladder and choledochal cyst across cases. The histological findings are not identical between individuals and should not be collapsed into one obligatory lesion.

cholangiocyte CL:1000488 intrahepatic cholangiocyte CL:0002538

Downstream

Progressive Cholestatic Liver Injury Impaired bile flow through a maldeveloped biliary tree produces cholestasis.

Biliary atresia The severe end of the biliary maldevelopment, presenting as obstructive liver disease in infancy.

Absent gallbladder Agenesis of the gallbladder as one reported form of the biliary maldevelopment.

Cyst of the ductus choledochus Choledochal cystic dilatation as another reported form of the biliary maldevelopment.

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Here we describe 11 additional individuals with HS, and reinforce the core phenotypes of orofacial clefting, aortic coarctation, genitourinary malformations and biliary dysgenesis"

Confirms biliary dysgenesis as a core feature in the largest reported cohort.

Progressive Cholestatic Liver Injury

Mechanism confidence: Established

Cholestasis presents in the neonatal or infantile period and, in severe cases, progresses through ductular change and fibrosis to cirrhosis, portal hypertension, variceal bleeding and liver failure requiring transplantation. This progression is supported by serial human clinical and biopsy observation, but a universal course is not established and some individuals remain biochemically affected without progressing.

hepatocyte CL:0000182

Downstream

Cholestasis

Hepatic fibrosis

Portal hypertension

Esophageal varix

Hepatic failure

Show evidence (2 references)

PMID:18792981 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."

Documents the progressive hepatobiliary course reaching transplantation in an individual case.

PMID:42510827 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."

Describes the decompensation sequence. Indirect because this individual's MED12 variant remained a variant of uncertain significance, so the case is clinically suggestive rather than molecularly confirmed.

Cardiac and Vascular Wall Vulnerability

Mechanism confidence: Hypothetical

The 2024 cohort added cardiomyopathy, arrhythmia and non-aortic vascular anomalies of the carotid, posterior cerebral, vertebral, pulmonary and renal vessels, and the gene-discovery series had already reported a fatal unprovoked intracranial hemorrhage at age 21. No mechanism for this arm is demonstrated: YAP and TGF-beta are plausible mediators, and the authors also allow that the cardiac disease may be independent of both ciliary and YAP effects. The node exists so the cardiovascular surveillance recommendation has something to attach to, and is marked HYPOTHETICAL accordingly.

Animal models

Cardiac-specific Med12 deletion mouse Mouse partially recapitulates Shows that tissue-restricted Med12 loss is sufficient for cardiomyopathy in mouse.

Downstream

Cardiomyopathy

Arrhythmia

Prolonged QT interval

Ventricular fibrillation

Cardiac conduction abnormality

Arterial aneurysm Aneurysmal dilatation of the carotid and posterior cerebral arteries, which with the vertebral aneurysm below is the vessel-wall half of this node.

Vertebral artery aneurysm

Intracranial hemorrhage The consequential event the vascular surveillance recommendation exists to pre-empt. Reported once in the vascular tabulation and once as a fatal unprovoked hemorrhage at age 21.

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein,..."

Establishes the cardiovascular phenotypes, with the specific arrhythmia types and vessels involved.

PMID:33244166 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"We report clinical features of HS with previously undescribed phenotypes, including a fatal unprovoked intracranial hemorrhage at age 21."

A vascular catastrophe in an affected individual. Indirect for this node because a single unprovoked hemorrhage does not by itself establish a vessel-wall mechanism.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

34

Blood 1

Intracranial hemorrhage HP:0002170

Show evidence (1 reference)

PMID:33244166 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We report clinical features of HS with previously undescribed phenotypes, including a fatal unprovoked intracranial hemorrhage at age 21."

A fatal intracranial hemorrhage in an affected young adult.

Cardiovascular 9

Coarctation of aorta HP:0001680

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT BACKGROUND Human Clinical

"Hardikar syndrome (HS, OMIM #301068) is an X-linked dominant disorder characterized by cleft lip/palate, pigmentary retinopathy, aortic coarctation, intestinal malrotation, hepatobiliary disease and genitourinary malformations with preserved neurocognition"

Lists aortic coarctation among the defining features.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Aortic Coarctation or Dilation | + | + | + | − | + | + | + | + | + | + | − | − | + | − | − | + | + | + | + | − | − | + | 15/22 (68%) |"

The cohort fraction behind the band, scoring coarctation or dilation together in 15 of 22 individuals.

Cardiomyopathy FREQUENT HP:0001638

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"With this cohort, we expand the phenotype of HS to include cardiomyopathy, arrhythmia, and vascular defects and we expand the molecular basis of HS to include splice MED12 variants."

Reports cardiomyopathy as a newly recognized phenotype.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Cardiomyopathy | + | − | + | − | − | + | + | + | + | − | − | − | − | − | − | − | − | − | − | − | − | − | 7/22 (32%) |"

Cardiomyopathy scored in 7 of 22 individuals, a one-to-one Table 1 row.

Arrhythmia OCCASIONAL HP:0011675

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein,..."

Names the arrhythmia subtypes observed.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"arrhythmia including atrial ectopy, ventricular fibrillation, and elongated QT interval (3/22; 14%)"

The cohort fraction behind the band, stated for arrhythmia specifically.

Prolonged QT interval HP:0001657

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein,..."

Reports QT prolongation specifically.

Ventricular fibrillation HP:0001663

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein,..."

Reports ventricular fibrillation among the observed arrhythmias.

Portal hypertension HP:0001409

Show evidence (1 reference)

PMID:42510827 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."

Reports portal hypertension. Indirect because the variant in this individual remained of uncertain significance.

Cardiac conduction abnormality OCCASIONAL HP:0031546

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Cardiac Conduction Abnormalities | − | + | − | − | − | − | − | − | + | − | − | − | − | + | NA | − | − | − | − | − | − | − | 3/21 (14%) |"

Cardiac conduction abnormality scored in 3 of 21 assessed individuals; this is the cohort-level counterpart of the arrhythmia subtypes recorded separately.

Arterial aneurysm Vascular dilatation HP:0002617

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein,..."

Names the non-aortic vessels involved, which is what this phenotype records.

PMID:39045790 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"| Vascular Malformation/Disease | + | − | − | − | − | + | + | + | + | + | − | − | + | − | NA | − | − | − | + | + | − | − | 9/21 (43%) |"

Vascular malformation or disease scored in 9 of 21 assessed individuals. Recorded as evidence for the category's presence; no band is set on this narrower finding.

Vertebral artery aneurysm HP:0034179

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein,..."

Names the vertebral arteries among the vessels involved. The Table 2 row for this lesion is too short to quote as a snippet on its own.

Digestive 10

Intestinal malrotation FREQUENT HP:0002566

Show evidence (2 references)

PMID:33244166 SUPPORT DIRECT BACKGROUND Human Clinical

"Hardikar syndrome (MIM 612726) is a rare multiple congenital anomaly syndrome characterized by facial clefting, pigmentary retinopathy, biliary anomalies, and intestinal malrotation, but with preserved cognition."

Lists intestinal malrotation among the defining features.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Intestinal Malrotation | + | + | − | − | − | + | − | + | + | − | + | − | + | − | + | − | − | + | + | + | − | − | 11/22 (50%) |"

Intestinal malrotation scored in 11 of 22 individuals.

Cholestasis HP:0001396

Show evidence (1 reference)

PMID:42510827 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."

Documents the cholestatic course. Indirect because the individual's MED12 variant remained of uncertain significance.

Biliary atresia HP:0005912

Show evidence (2 references)

PMID:33244166 SUPPORT DIRECT BACKGROUND Human Clinical

"Hardikar syndrome (MIM 612726) is a rare multiple congenital anomaly syndrome characterized by facial clefting, pigmentary retinopathy, biliary anomalies, and intestinal malrotation, but with preserved cognition."

Biliary anomalies are a defining feature; biliary atresia is the severe reported form.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Biliary/Gallbladder Malformation | − | + | + | − | + | + | + | − | + | + | + | − | + | + | − | + | + | + | + | + | + | − | 16/22 (73%) |"

Biliary or gallbladder malformation scored in 16 of 22 individuals, the cohort fraction behind the band.

Absent gallbladder HP:0011467

Show evidence (1 reference)

PMID:42510827 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"We describe a female infant who presented with progressive cholestatic liver disease and complex hepatobiliary malformations, including an absent gallbladder and paucity of bile ducts, with unremarkable prenatal imaging."

Reports absent gallbladder and bile-duct paucity. Indirect because the variant in this individual remained of uncertain significance.

Cyst of the ductus choledochus HP:0100890

Show evidence (1 reference)

PMID:18792981 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."

First report of a type 1 choledochal cyst in this syndrome.

Hepatic fibrosis HP:0001395

Show evidence (2 references)

PMID:18792981 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."

Attests the progressive liver disease that reached transplantation. Indirect for fibrosis specifically, which the quoted sentence does not name.

PMID:42510827 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"At 1 month: bile duct proliferation + fibrosis; at 7.5 months: cirrhosis with regenerating nodules + chronic portal inflammation with bile duct proliferation + lobular cholestasis"

Histology naming fibrosis directly, and dating its progression to cirrhosis, in the molecularly confirmed 2008 case. This is the direct evidence for hepatic fibrosis; the sibling item above attests only the clinical course.

Esophageal varix HP:0002040

Show evidence (1 reference)

PMID:42510827 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."

Reports esophageal varices. Indirect because the variant in this individual remained of uncertain significance.

Hepatic failure HP:0001399

Show evidence (1 reference)

PMID:42510827 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."

Reports progression to liver failure. Indirect because the variant in this individual remained of uncertain significance.

Constipation OCCASIONAL HP:0002019

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Constipation | − | − | + | − | − | + | + | + | + | − | − | − | − | − | NA | − | − | − | − | − | − | + | 6/21 (29%) |"

Constipation scored in 6 of 21 assessed individuals, a one-to-one Table 1 row.

Meckel diverticulum OCCASIONAL HP:0002245

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Meckel’s Diverticulum | − | − | − | − | + | + | − | + | + | − | + | − | − | − | − | − | − | − | − | − | + | − | 6/22 (27%) |"

Meckel's diverticulum scored in 6 of 22 individuals, a one-to-one Table 1 row.

Ear 1

Hearing impairment HP:0000365

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We previously recommended based on our patient cohort that individuals with HS be screened for orofacial clefting and velopharyngeal insufficiency, retinopathy, congenital heart disease, aortic coarctation, carotid and aortic dilation, cerebral vascular malformations, biliary disease, intestinal..."

Hearing loss is named as a feature warranting screening in this syndrome.

Eye 1

Pigmentary retinopathy FREQUENT HP:0000580

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Our previously-published HS cohort highlighted core features of HS, including orofacial clefting, aortic coarctation, intestinal malrotation, ectopic ureters, biliary abnormalities, and cat's paw retinopathy (patchy retinal pigmentation)."

Names the characteristic retinal appearance, which is the specificity carried in preferred_term above the coarser HPO term.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Retinal Abnormalities | − | + | + | − | Unknown | + | + | − | + | − | − | − | + | + | NA | − | − | + | + | + | + | − | 11/20 (55%) |"

Retinal abnormality scored in 11 of 20 assessed individuals.

Genitourinary 4

Hydronephrosis HP:0000126

Show evidence (2 references)

PMID:42510827 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"| GU—hydronephrosis (HP:0000126) | Bilateral | Bilateral | NA | NA | NA | Bilateral | NA | Yes, bilateral | NA |"

Names hydronephrosis directly, bound to the same HPO term, and records it as bilateral in four of the compiled individuals. Replaces an earlier citation to a sentence that said only "genitourinary malformations".

PMID:39045790 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"| Genitourinary Abnormalities | + | + | + | − | + | + | + | + | + | + | + | − | + | + | + | + | + | + | + | + | + | − | 19/22 (86%) |"

The cohort-level fraction the band is taken from: genitourinary abnormality in 19 of 22 individuals.

Vesicoureteral reflux HP:0000076

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We previously recommended based on our patient cohort that individuals with HS be screened for orofacial clefting and velopharyngeal insufficiency, retinopathy, congenital heart disease, aortic coarctation, carotid and aortic dilation, cerebral vascular malformations, biliary disease, intestinal..."

Vesicoureteral reflux is named as a feature warranting screening in this syndrome.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Genitourinary Abnormalities | + | + | + | − | + | + | + | + | + | + | + | − | + | + | + | + | + | + | + | + | + | − | 19/22 (86%) |"

Genitourinary abnormality scored in 19 of 22 individuals, the cohort fraction behind the band.

Ectopic ureteral orifice HP:6000413

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Our previously-published HS cohort highlighted core features of HS, including orofacial clefting, aortic coarctation, intestinal malrotation, ectopic ureters, biliary abnormalities, and cat's paw retinopathy (patchy retinal pigmentation)."

Names ectopic ureters among the core features.

Vaginal atresia HP:0000148

Show evidence (1 reference)

PMID:18792981 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."

The first report of vaginal atresia in this syndrome.

Head and Neck 5

Cleft lip HP:0410030

Show evidence (2 references)

PMID:18792981 SUPPORT DIRECT BACKGROUND Human Clinical

"Hardikar syndrome (HS) is a disorder of multiple anomalies predominantly characterized by cleft lip/palate, liver and biliary tract disease, intestinal malrotation, obstructive uropathy, and retinopathy."

Lists cleft lip/palate among the defining features.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Orofacial Clefting | − | + | − | + | + | + | − | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 18/22 (82%) |"

Table 1 scores orofacial clefting in 18 of 22 molecularly confirmed females, which is the basis for the VERY_FREQUENT band.

Cleft palate HP:0000175

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Here we describe 11 additional individuals with HS, and reinforce the core phenotypes of orofacial clefting, aortic coarctation, genitourinary malformations and biliary dysgenesis"

Reinforces orofacial clefting as a core phenotype in the largest cohort.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Orofacial Clefting | − | + | − | + | + | + | − | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 18/22 (82%) |"

The cohort fraction behind the band: 18 of 22 molecularly confirmed females.

Preauricular pit HP:0004467

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Ears Pits/Tags/Branchial Cleft | + | − | + | + | + | + | + | + | + | − | + | − | + | + | NA | + | + | + | − | + | + | + | 17/21 (81%) |"

Ear pits, tags or branchial cleft anomalies scored in 17 of 21 assessed individuals, the highest fraction in the cohort table.

Preauricular skin tag HP:0000384

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Ears Pits/Tags/Branchial Cleft | + | − | + | + | + | + | + | + | + | − | + | − | + | + | NA | + | + | + | − | + | + | + | 17/21 (81%) |"

Ear pits, tags or branchial cleft anomalies scored in 17 of 21 assessed individuals, the highest fraction in the cohort table.

Branchial anomaly HP:0009794

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Ears Pits/Tags/Branchial Cleft | + | − | + | + | + | + | + | + | + | − | + | − | + | + | NA | + | + | + | − | + | + | + | 17/21 (81%) |"

Ear pits, tags or branchial cleft anomalies scored in 17 of 21 assessed individuals, the highest fraction in the cohort table.

Musculoskeletal 2

Scoliosis OCCASIONAL HP:0002650

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Musculoskeletal | − | Scoliosis | − | − | − | − | Scoliosis, syndactyly | Scoliosis | − | − | Sacral dimple | Digit anomalies | Vertebral abnormalities | − | − | − | − | − | − | − | − | Hip dysplasia | 7/22 (32%) |"

The row this band is counted from. Scoliosis appears in 3 of the 22 cells; the row's 7/22 total is the whole musculoskeletal category.

Congenital diaphragmatic hernia OCCASIONAL HP:0000776

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"| Diaphragmatic Hernia | − | − | − | + | + | − | + | − | − | − | + | − | − | − | + | − | + | − | − | − | − | − | 6/22 (27%) |"

Diaphragmatic hernia scored in 6 of 22 individuals, a one-to-one Table 1 row.

Growth 1

Short stature OCCASIONAL HP:0004322

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

The row this band is counted from. Short stature is named in 3 of the 22 cells; the remaining five of the row's 8/22 total are small size or low weight.

🧬

Genetic Associations

1

MED12

Gene: MED12 hgnc:11957 gene page relationship_type: CAUSATIVE variant_origin: DE_NOVO

X-linked Dominant

Show evidence (2 references)

PMID:33244166 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We propose a fifth, female-specific phenotype for MED12, and suggest that nonsense and frameshift loss-of-function MED12 variants in females cause HS."

Establishes MED12 as the causative gene for this disorder.

PMID:33244166 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We performed exome sequencing on two previously reported and five unpublished female patients with a clinical diagnosis of HS."

The ascertainment and method behind the gene-disease assignment.

Variants (1)

MED12 c.3868-5C>G Uncertain Significance

Gene: MED12 hgnc:11957

De novo intronic variant reported in an infant with a predominantly hepatobiliary presentation. Its predicted splice-acceptor effect was not tested at the RNA or protein level and its own authors retained a variant-of-uncertain-significance classification, so it is recorded here as a candidate allele and not as evidence that splice disruption is an established mechanism.

Show evidence (2 references)

PMID:42510827 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"WES identified a novel de novo intronic heterozygous variant in MED12 (c.3868-5C>G)."

Reports the variant and its de novo heterozygous status.

PMID:42510827 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The identified MED12 variant is classified as a variant of uncertain significance (VUS)."

The authors' own classification, which is why this entry does not treat the allele as pathogenic.

💊

Medical Actions

2

Ladd Procedure

Action: Ladd procedure Ontology label: Ladd Procedure NCIT:C168307

Platform: Surgery

Surgical correction of intestinal malrotation, performed in a reported case presenting with neonatal obstruction.

Target Phenotypes: Intestinal malrotation HP:0002566

Show evidence (1 reference)

PMID:18792981 SUPPORT INDIRECT BACKGROUND Human Clinical

"Hardikar syndrome (HS) is a disorder of multiple anomalies predominantly characterized by cleft lip/palate, liver and biliary tract disease, intestinal malrotation, obstructive uropathy, and retinopathy."

Establishes intestinal malrotation as a feature of the syndrome, which is what this operation addresses. Indirect because the quoted sentence names the malformation and not the operation; the abstract does not name the procedure, which is why no stronger quote is attached.

Liver Transplantation

Action: liver transplantation Ontology label: Liver Transplantation NCIT:C15271

Platform: Surgery

Performed for end-stage liver disease arising from the progressive cholestatic course. Jaundice resolved and growth improved after transplantation in the reported case, while urinary infections recurred.

Mechanism Target:

Progressive Cholestatic Liver Injury — Replaces the failing organ; does not address the extrahepatic congenital malformations.

Show evidence (1 reference)

PMID:18792981 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."

Documents the need for liver transplantation in this syndrome.

🔬

Diagnosis

3

Trio exome or genome sequencing covering MED12

Molecular diagnosis rests on sequencing that covers MED12 with parental segregation, interpreted against variant class, phenotype and possible mosaicism. The assay needs to reach splice-region changes and copy-number variation: the 2024 cohort extended the allele class to splice-site variants, and an intragenic MED12 deletion has been reported, so a normal sequencing result on a limited assay does not exclude the diagnosis.

Show evidence (1 reference)

PMID:33244166 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We performed exome sequencing on two previously reported and five unpublished female patients with a clinical diagnosis of HS."

The method by which the molecular diagnosis was established in the gene-discovery series.

Cardiac, arrhythmia and vascular surveillance

Regular cardiac imaging, arrhythmia screening and vascular imaging, added to the recommended standard of care by the 2024 cohort on the strength of the newly recognized cardiomyopathy, arrhythmia and non-aortic vascular anomalies. The source states three specific schedules: an annual echocardiogram for cardiomyopathy, a lifelong annual EKG with 24-hour Holter monitor for arrhythmia, and a baseline total-body MRA with and without gadolinium repeated at least every two years for vascular malformations, with later scans done without gadolinium if the baseline is normal. These are case-series expert recommendations, not prospectively validated intervals.

Filed under diagnosis rather than treatments because echocardiography, arrhythmia monitoring and vascular imaging are diagnostic procedures. The cost of filing it here is that `Diagnosis` has no `target_mechanisms`, so the link to the `Cardiac and Vascular Wall Vulnerability` pathophysiology node that motivates the surveillance is stated in prose rather than carried as an edge.

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Our data support updating HS standard-of-care to include regular cardiac imaging, arrhythmia screening, and vascular imaging."

The surveillance recommendation and the cohort data behind it.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Based on our expanded cohort and recent reports, we additionally recommend 1) annual echocardiogram to screen for cardiomyopathy, 2) lifelong annual EKG and 24-hour Holter monitor to screen for arrhythmia, and 3) baseline total body MRA with and without contrast (gadolinium) with repeat imaging..."

The three specific surveillance schedules the cohort recommends, with their intervals. An earlier version of this entry said the source gave no interval; this is the sentence that shows it does.

Multisystem evaluation at diagnosis

The 2024 cohort's recommended workup spans the organ systems the syndrome malforms: orofacial clefting and velopharyngeal insufficiency, retinopathy, congenital heart disease and aortic coarctation, carotid and aortic dilation, cerebral vascular malformations, biliary disease, intestinal malrotation, genitourinary abnormalities, vesicoureteral reflux and hearing loss.

Show evidence (1 reference)

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We previously recommended based on our patient cohort that individuals with HS be screened for orofacial clefting and velopharyngeal insufficiency, retinopathy, congenital heart disease, aortic coarctation, carotid and aortic dilation, cerebral vascular malformations, biliary disease, intestinal..."

The recommended multisystem evaluation, as stated by the cohort that proposed it.

📊

Prevalence

1

Reported cases worldwide

Cases In Literature Ultra Rare

Literature-ascertained case count, not a measured prevalence. Seven molecularly characterized females in the 2021 gene-discovery series, eleven further individuals in the 2024 cohort, and 34 cases counted as previously reported by a 2026 review. Incidence, prevalence, penetrance and carrier frequency are all unknown. This is a statement about population occurrence only. It is not a claim that no phenotype denominator exists: Table 1 of PMID:39045790 is a per-individual phenotype table over 22 molecularly confirmed females and carries a fraction on every row, and the phenotype `frequency` bands in this entry are derived from it.

Show evidence (1 reference)

PMID:42510827 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Only 34 cases have been reported to date, and most exhibit multiple congenital anomalies."

Gives the literature case count this ultra-rare classification rests on.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Hardikar Syndrome:

Alagille syndrome

Overlapping Features Shares cholestasis, cardiac and ocular involvement. The 2008 report speculated that the two conditions might be genetically related on the strength of that overlap; no JAG1 or NOTCH2 lesion has been demonstrated in Hardikar syndrome, and the speculation predates the identification of MED12.

Show evidence (1 reference)

PMID:18792981 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"It is intriguing to speculate, that HS could be genetically related to Alagille syndrome (AS), since both conditions share an unusual number of phenotypic abnormalities."

The source of the Alagille comparison, quoted so that its status as explicit speculation is visible in the entry.

MED12-related intellectual disability syndrome Not Yet Curated MONDO:0100000

Overlapping Features The hemizygous male arm of the MED12 series (FG/Opitz-Kaveggia, Lujan, X-linked Ohdo), caused by recurrent missense alleles and dominated by intellectual disability. Hardikar syndrome is distinguished by truncating alleles, female sex, and characteristically preserved neurocognition.

Distinguishing Features

Truncating (nonsense, frameshift, splice) MED12 alleles, versus recurrent missense alleles in the male syndromes.
Affected individuals are female; the male syndromes affect hemizygous males.
Neurocognition is characteristically preserved, where intellectual disability defines the male syndromes.

Show evidence (2 references)

PMID:39045790 SUPPORT DIRECT BACKGROUND Human Clinical

"This contrasts to HS, which is caused predominantly by nonsense/frameshift MED12 variants and is characterized by normal neurocognition"

States the allele-class and cognitive distinction between the two arms.

PMID:39045790 SUPPORT DIRECT PRIMARY RESULT Human Clinical

The cohort measurement behind "preserved neurocognition", and the strongest evidence for the distinction this differential rests on: development was scored abnormal in only 1 of 20 assessed individuals, and that individual is annotated as having medical complexity. This is the direct counterpart to the BACKGROUND sentences elsewhere in the entry that assert preserved cognition.

🐁

Animal Models

1

Cardiac-specific Med12 deletion mouse

Cited in the 2024 Hardikar cohort as supporting evidence that MED12 loss can produce cardiac disease. Recorded because it is the only model evidence bearing on the cardiovascular arm of this syndrome.

Species

Mouse

Genotype

Cardiac-specific Med12 deletion

Publication

PMID:39045790

Pathograph links

Cardiac and Vascular Wall Vulnerability partially recapitulates fidelity: low observes: organism Shows that tissue-restricted Med12 loss is sufficient for cardiomyopathy in mouse.

Limitations: A cardiac-restricted conditional deletion is not the human genotype, which is a constitutive heterozygous truncating allele on one X chromosome subject to X-inactivation. The model speaks to cardiomyopathy alone and not to the arrhythmia or extracardiac vascular anomalies, and this entry cites it only through the 2024 paper's summary rather than from the primary report.

Divergences from the human mechanism

population mismatch qualifying

Homozygous tissue-restricted deletion in mouse against constitutive heterozygous truncation with skewed X-inactivation in human females; the dosage and its mosaicism across tissues are not comparable.

boundary omission qualifying

The model is restricted to heart, so the vascular anomalies of the carotid, cerebral, vertebral, pulmonary and renal vessels reported in patients are outside it entirely.

Show evidence (1 reference)

PMID:39045790 SUPPORT INDIRECT BACKGROUND Model Organism

"Of note, cardiac-specific MED12 deletion in mice caused dilated cardiomyopathy and a missense MED12 variant was identified in an individual with dilated cardiomyopathy"

The model result as reported in the Hardikar cohort paper. Graded BACKGROUND because that paper is restating two prior studies rather than reporting its own mouse work.

{ }

Source YAML

click to show

name: Hardikar Syndrome
creation_date: "2026-10-09T20:30:00Z"
category: Mendelian
description: >-
  Hardikar syndrome is a female-specific X-linked dominant multiple congenital
  anomaly syndrome caused by de novo heterozygous truncating variants in MED12,
  the scaffold subunit of the Mediator kinase module. Its recurrent features are
  orofacial clefting, pigmentary retinopathy, aortic coarctation, biliary
  dysgenesis with progressive cholestatic liver disease, genitourinary
  malformations and intestinal malrotation, with neurocognition typically
  preserved. A 2024 cohort added cardiomyopathy, arrhythmia and non-aortic
  vascular anomalies to the phenotype, and extended the molecular spectrum from
  nonsense and frameshift variants to splice-site variants. The syndrome is the
  loss-of-function arm of the MED12 allelic series: the hemizygous male
  syndromes (FG/Opitz-Kaveggia, Lujan, X-linked Ohdo) arise from recurrent
  missense alleles and are dominated by intellectual disability, which Hardikar
  syndrome characteristically lacks. Mechanistically, MED12 deficiency reduces
  primary ciliation and lowers Hedgehog and YAP/TEAD pathway output, which is
  the current proposed basis for the malformation pattern.
disease_term:
  preferred_term: Hardikar syndrome
  term:
    id: MONDO:0012997
    label: cholestasis-pigmentary retinopathy-cleft palate syndrome
synonyms:
- Hardikar syndrome
- HDKR
- MED12-related Hardikar syndrome
- cholestasis-pigmentary retinopathy-cleft palate syndrome
notes: >-
  Two OMIM numbers appear in the literature for this concept and both are
  correct as written by their sources: Li et al. cite MIM 612726 and Strong et
  al. cite OMIM #301068, and MONDO:0012997 carries both xrefs. OMIM #300188 is
  the MED12 gene entry, not the phenotype. Neither citation is corrected in the
  snippets below.

  Reported case counts are literature compilations, not population
  denominators, so there is no incidence or prevalence figure here. Li et al.
  molecularly characterized seven females, Strong et al. added eleven, and the
  2026 case report counts 34 previously reported cases before its own.

  Phenotype frequency is a different question and does have a denominator.
  Table 1 of PMID:39045790 scores each phenotype across 22 molecularly confirmed
  females and reports a fraction per row.

  A `frequency` band is only set where that fraction is about the phenotype it
  sits on. Three cases, and the rule matters because `frequency` is a structured
  claim that a query reads without the surrounding description:

  - A row that names one finding gives that finding its band directly -
    intestinal malrotation, cardiomyopathy, constipation, Meckel diverticulum,
    congenital diaphragmatic hernia, cardiac conduction abnormality. Arrhythmia
    takes its band from the same paper's prose figure, which is also one-to-one.
    Pigmentary retinopathy takes the `Retinal Abnormalities` row because the
    patchy pigmentary change is the only retinal feature the source describes.
  - A row whose *cells* name the finding gives a band counted from the cells, not
    from the row total: scoliosis in 3 of 22, short stature in 3 of 22, against
    row totals of 7/22 and 8/22 for the whole musculoskeletal and growth
    categories.
  - A row that scores a *category* gives no band to its members.
    `Orofacial Clefting`, `Genitourinary Abnormalities`,
    `Biliary/Gallbladder Malformation`, `Ears Pits/Tags/Branchial Cleft` and
    `Aortic Coarctation or Dilation` are all of this kind. Their fractions are
    recorded in the member phenotypes' descriptions and quoted as evidence, but
    no band is set, because 86% of patients did not have hydronephrosis and 82%
    did not have cleft lip - those are the figures for any genitourinary anomaly
    and any orofacial cleft. Table 2 gives no bands either: its vessel counts are
    over the whole reported set rather than fractions of the 22-individual
    cohort.

  Every band here comes from one ascertained clinical series, so it describes who
  was recruited and investigated rather than a population rate.

  The 2026 case report (PMID:42510827) is cited only for the phenotypic
  observation that a predominantly hepatobiliary presentation occurs and for
  the existence of a candidate intronic allele. Its variant, MED12
  c.3868-5C>G, was retained by its own authors as a variant of uncertain
  significance with no RNA or protein validation, so it is recorded in
  `variants` as UNCERTAIN_SIGNIFICANCE and is not counted as a molecularly
  confirmed case or as evidence for a splice mechanism.

  Not cited, and why. The 1992 Hardikar and 1997 Cools and Jaeken reports that
  named the syndrome predate molecular diagnosis and are referred to only
  through Poley and Proud's summary of them. KDM6A and KMT2D appear in the
  MED12 literature as a transcriptional-network comparison with Kabuki
  syndrome; they are not Hardikar causal or modifier genes and are not recorded
  here. The 2008 suggestion that Hardikar syndrome might be genetically related
  to Alagille syndrome was explicitly speculation by its authors and JAG1 is
  carried only as a differential diagnosis, not as a mechanism.
prevalence:
- population: Reported cases worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Literature-ascertained case count, not a measured prevalence. Seven
    molecularly characterized females in the 2021 gene-discovery series, eleven
    further individuals in the 2024 cohort, and 34 cases counted as previously
    reported by a 2026 review. Incidence, prevalence, penetrance and carrier
    frequency are all unknown.

    This is a statement about population occurrence only. It is not a claim that
    no phenotype denominator exists: Table 1 of PMID:39045790 is a per-individual
    phenotype table over 22 molecularly confirmed females and carries a fraction
    on every row, and the phenotype `frequency` bands in this entry are derived
    from it.
  evidence:
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Only 34 cases have been reported to date, and most exhibit multiple congenital anomalies."
    explanation: Gives the literature case count this ultra-rare classification rests on.
inheritance:
- name: X-linked Dominant
  inheritance_term:
    preferred_term: X-linked dominant inheritance
    term:
      id: HP:0001423
      label: X-linked dominant inheritance
  description: >-
    Heterozygous truncating MED12 variants on the X chromosome produce disease
    in females. Whether severe male loss-of-function genotypes are embryonically
    lethal is an inference drawn from the exclusively female ascertainment, not
    a measured penetrance.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Hardikar syndrome (HS, OMIM #301068) is an X-linked dominant disorder characterized by cleft lip/palate, pigmentary retinopathy, aortic coarctation, intestinal malrotation, hepatobiliary disease and genitourinary malformations with preserved neurocognition"
    explanation: >-
      States the inheritance mode and the core phenotype. Graded BACKGROUND
      because it is the paper's introductory restatement of the two earlier
      clinical reports, not a result of the cohort described in it.
- name: De Novo Occurrence
  inheritance_term:
    preferred_term: Sporadic
    term:
      id: HP:0003745
      label: Sporadic
  description: >-
    Most molecularly characterized cases arose de novo. Mosaicism has been
    suspected in at least one individual, so a zero recurrence risk should not
    be assumed without parental testing.
  evidence:
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We additionally report the discovery of de novo pathogenic nonsense and frameshift variants in MED12 in these seven individuals and evidence of extremely skewed XCI in all patients with informative testing."
    explanation: Establishes de novo occurrence in the gene-discovery cohort.
pathophysiology:
- name: MED12 Truncating Loss of Function
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    De novo heterozygous nonsense, frameshift or splice-site variants in MED12
    remove functional protein from one X-linked allele. This allele class is
    what distinguishes Hardikar syndrome from the rest of the MED12 series: the
    hemizygous male syndromes arise from recurrent missense alleles, and somatic
    missense variants in the same gene drive uterine leiomyoma.
  genetic_context:
    variant_origin: DE_NOVO
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Nonsense and frameshift alleles predicted to trigger nonsense-mediated
      decay, plus splice-site alleles added by the 2024 cohort.
  genes:
  - preferred_term: MED12
    term:
      id: hgnc:11957
      label: MED12
  evidence:
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We propose a fifth, female-specific phenotype for MED12, and suggest that nonsense and frameshift loss-of-function MED12 variants in females cause HS."
    explanation: >-
      The gene-discovery conclusion: truncating loss-of-function MED12 alleles
      in females cause this syndrome, as a distinct entity within the MED12
      series.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "HS is specifically associated with de novo nonsense and frameshift MED12 variants"
    explanation: Confirms the allele class is specific to this disorder within the MED12 series.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We report novel phenotypes associated with HS, including cardiomyopathy, arrhythmia, and vascular anomalies, and expand the molecular landscape of HS to include splice site variants."
    explanation: Extends the allele class from nonsense and frameshift to splice-site variants.
  downstream:
  - target: Reduced MED12 Dosage in the Mediator Kinase Module
    causal_link_type: DIRECT
    description: >-
      A truncating allele removes functional MED12 from the dissociable kinase
      module of Mediator.
- name: Extremely Skewed X-Chromosome Inactivation
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    All informatively tested individuals in the gene-discovery series showed
    extremely skewed X-chromosome inactivation. This is measured in accessible
    tissue, usually blood, and so constrains but does not establish which allele
    is expressed in liver, retina or any other affected organ; it is recorded
    here as a modifier of expression rather than as the initiating lesion.
  genes:
  - preferred_term: MED12
    term:
      id: hgnc:11957
      label: MED12
  evidence:
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We additionally report the discovery of de novo pathogenic nonsense and frameshift variants in MED12 in these seven individuals and evidence of extremely skewed XCI in all patients with informative testing."
    explanation: Reports the skewed X-inactivation finding in every informatively tested patient.
  notes: >-
    No ontology term is bound on this node. HPO's inheritance subtree has no
    term for skewed X-inactivation as a cellular state, and the GO X-inactivation
    terms describe the normal developmental process rather than its skewing, so
    binding one with a modifier would assert a defect in the inactivation
    machinery that no source claims. Searched `runoak -i ols:go search
    'l~X-inactivation'` and `runoak -i ols:hp search 'l~X-inactivation'`.
  downstream:
  - target: Reduced MED12 Dosage in the Mediator Kinase Module
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Skewing determines what fraction of cells in a given tissue express the
      intact allele, and so modulates effective MED12 dosage per organ. Which
      direction the skewing runs in each affected organ is not established.
- name: Reduced MED12 Dosage in the Mediator Kinase Module
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    MED12 is the scaffold subunit of the four-part Mediator kinase module
    (MED12, MED13, CCNC, CDK8), a dissociable regulatory cap on core Mediator.
    Reduced MED12 lowers the module's contribution to transcriptional
    regulation, including MED12's own interactions with chromatin and
    transcription factors.
  genes:
  - preferred_term: MED12
    term:
      id: hgnc:11957
      label: MED12
  molecular_functions:
  - preferred_term: transcription coregulator activity
    term:
      id: GO:0003712
      label: transcription coregulator activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: transcription by RNA polymerase II
    term:
      id: GO:0006366
      label: transcription by RNA polymerase II
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    quote_role: BACKGROUND
    snippet: "MED12 interacts with chromatin and transcription factors to modulate chromatin architecture and transcriptional activity"
    explanation: >-
      States the molecular function lost when MED12 dosage falls, which is what
      the GO:0003712 binding records. Graded OTHER with quote_role BACKGROUND
      because the sentence is the paper's introductory summary of three prior
      studies rather than its own result.
  notes: >-
    Bound to GO:0003712 transcription coregulator activity rather than its child
    GO:0003713 transcription coactivator activity. Both are live and both are
    already used elsewhere in the KB, but the CDK8 kinase module has activating
    and repressive roles in transcription, so coactivator would assert a
    direction the module does not uniformly have. MED12 itself is the module's
    scaffold and carries no catalytic activity, so the coregulator term is the
    protein-level function that reduced MED12 dosage lowers; the RNA polymerase II
    process term below is the cell-level consequence.
  downstream:
  - target: Impaired Primary Ciliogenesis
    causal_link_type: DIRECT
    description: >-
      MED12 is required to sustain primary ciliation; its loss reduces the
      proportion of ciliated cells.
    evidence:
    - reference: PMID:39045790
      reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: "siRNA-mediated MED12 knockdown in RPE cells reduced percent ciliated cells by 15% without affecting ciliary length"
      explanation: >-
        Direct measurement of the ciliation defect on MED12 knockdown, and of
        its shape: fewer ciliated cells, not shorter cilia.
  - target: Impaired YAP-TEAD Transcriptional Output
    causal_link_type: DIRECT
    description: >-
      MED12 loss lowers YAP/TEAD-driven transcription without reducing YAP
      itself.
    evidence:
    - reference: PMID:39045790
      reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: "We demonstrate that siRNA-mediated MED12 knockdown decreases YAP signaling in RPE cells."
      explanation: Direct measurement of reduced YAP pathway activity on MED12 knockdown.
- name: Impaired Primary Ciliogenesis
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    MED12 expression rises about two-fold in cells induced to form primary cilia
    and falls by about half during ciliary disassembly, and its knockdown reduces
    the ciliated fraction without shortening cilia. The reduction is not
    explained by cells cycling faster, since knockdown also halves proliferation.
    This places Hardikar syndrome partly within ciliopathy-spectrum biology,
    which is where its retinopathy, biliary dysgenesis and fibrotic liver disease
    overlap clinically.
  biological_processes:
  - preferred_term: non-motile cilium assembly
    term:
      id: GO:1905515
      label: non-motile cilium assembly
    modifier: DECREASED
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "Serum-starved RPE cells undergoing ciliogenesis had a 2-fold increase in MED12 expression compared to cells treated with complete medium"
    explanation: MED12 is upregulated when cells build primary cilia, supporting a role in ciliogenesis.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "RPE cells treated with serum and undergoing ciliary disassembly had a 50% reduction in MED12 expression, supporting a role for MED12 in the inhibition of ciliary disassembly"
    explanation: The reciprocal observation during ciliary disassembly.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "Cells transfected with MED12 siRNA had a ~50% reduction in cell proliferation, suggesting that the decrease in percent ciliated cells is not due to increased proliferation"
    explanation: >-
      Excludes the main alternative explanation for a lower ciliated fraction.
      Indirect because it supports the claim by ruling out a confounder rather
      than by measuring ciliogenesis.
  notes: >-
    Bound to GO:1905515 non-motile cilium assembly rather than the broader
    GO:0060271 cilium assembly, because the experiments are in serum-starved
    retinal pigment epithelial cells assaying the primary cilium, and the source
    states that a transcriptional program for primary ciliogenesis specifically
    had not previously been described. Cell type is recorded as the RPE line the
    measurements were made in; no patient-cell atlas establishes which cell types
    lose cilia in affected organs.
  downstream:
  - target: Impaired Hedgehog Pathway Activation
    causal_link_type: DIRECT
    description: >-
      The primary cilium houses the Hedgehog pathway, and an intact cilium is
      required for the response to a Smoothened agonist. Knockdown of the
      independent ciliogenesis factor TTBK2 reduced ciliation and abolished the
      same response, so the cilium rather than MED12 itself is the proximate
      requirement.
  - target: Disrupted Developmental Organogenesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reduced ciliary signaling during development is the proposed route to the
      ciliopathy-like features: retinopathy, biliary dysgenesis and fibrotic
      liver disease. Which cells lose cilia in which organ, and when, is not
      demonstrated.
- name: Impaired Hedgehog Pathway Activation
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    MED12-deficient cells fail to induce GLI1 in response to the Smoothened
    agonist SAG, which control cells do robustly. The direction of this effect
    is the opposite of what earlier work on MED12 and Hedgehog reported, and the
    discrepancy is unresolved; see discussion hardikar_med12_hedgehog_direction.
  biological_processes:
  - preferred_term: smoothened signaling pathway
    term:
      id: GO:0007224
      label: smoothened signaling pathway
    modifier: DECREASED
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "Cells treated with control siRNA had a robust induction of GLI1 expression in response to SAG; MED12 deficiency abrogated the response"
    explanation: >-
      Direct measurement of the Hedgehog signaling defect, read out as loss of
      agonist-induced GLI1 induction.
  downstream:
  - target: Disrupted Developmental Organogenesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Hedgehog signaling patterns many of the structures malformed in this
      syndrome. The organ-by-organ assignment is inferred from pathway biology
      rather than demonstrated in patient tissue.
- name: Impaired YAP-TEAD Transcriptional Output
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    MED12 knockdown lowers expression of the YAP target genes CTGF and CYR61 and
    reduces TEAD-responsive reporter activity. The effect is not explained by
    less YAP protein: YAP mRNA rises and phosphorylated YAP falls, which the
    authors read as attempted compensation. Their model is that MED12 directly
    enhances YAP/TEAD-mediated transcription.
  biological_processes:
  - preferred_term: YAP/TEAD-mediated gene transcription
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
    modifier: DECREASED
  cellular_components:
  - preferred_term: TEAD-YAP complex
    term:
      id: GO:0140552
      label: TEAD-YAP complex
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "These data are most consistent with a model in which MED12 directly enhances YAP/TEAD-mediated gene transcription."
    explanation: >-
      The authors' mechanistic reading of their own YAP target-gene and
      reporter data, which is what this node asserts.
  notes: >-
    Deliberately not bound to GO:0035329 hippo signaling. That term denotes the
    Hippo kinase cascade, which *inhibits* YAP, so attaching it with a DECREASED
    modifier would assert the opposite of the source: here YAP/TEAD
    transcriptional output falls while phosphorylated YAP, the product of that
    cascade, also falls. Searched `runoak -i ols:go search 'l~Hippo'` (returns
    GO:0035329 and its regulation children), `l~TEAD` (returns only the
    component GO:0140552) and `l~transcription coactivator activity` (no hits).
    GO has no biological-process term for YAP/TEAD-driven transcription, so the
    process slot carries the broader RNA polymerase II regulation term with the
    specific claim in `preferred_term`, and the YAP/TEAD identity is kept
    queryable through the GO:0140552 cellular component.
  downstream:
  - target: Disrupted Developmental Organogenesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      YAP signaling has established roles in orofacial clefting and
      angiogenesis, both features of this syndrome.
  - target: Cardiac and Vascular Wall Vulnerability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Proposed, not demonstrated. The authors note that YAP and TGF-beta
      signaling modulate angiogenesis and cardiomyopathy, and separately that
      heart disease in this syndrome may arise independently of ciliary and YAP
      effects. Recorded as the leading hypothesis for the cardiovascular arm.
- name: Disrupted Developmental Organogenesis
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  description: >-
    Reduced ciliary, Hedgehog and YAP/TEAD output during embryogenesis is the
    proposed common cause of the structural malformations. The lesion responsible
    for each individual human feature has not been demonstrated, and the
    malformations are established prenatally, so they are persistent rather than
    progressive after birth.
  biological_processes:
  - preferred_term: digestive tract morphogenesis
    term:
      id: GO:0048546
      label: digestive tract morphogenesis
    modifier: ABNORMAL
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "We propose a model in which loss of MED12 interferes with the transcription of genes critical for ciliogenesis and also impairs YAP pathway activation, leading to the severe developmental abnormalities characteristic of HS"
    explanation: >-
      The proposed mechanism linking the measured molecular defects to the
      malformation pattern. Stated by its authors as a model, which is why this
      node is PROVISIONAL.
  downstream:
  - target: Biliary Dysgenesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Maldevelopment of the intra- and extrahepatic biliary tree.
  - target: Cleft lip
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cleft palate
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Pigmentary retinopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Intestinal malrotation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Coarctation of aorta
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hydronephrosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Vesicoureteral reflux
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Ectopic ureteral orifice
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hearing impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Preauricular pit
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Preauricular skin tag
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Branchial anomaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Preauricular pits and tags and branchial cleft anomalies are all first and
      second pharyngeal arch derivatives, which is consistent with their being the
      most frequent feature in the cohort.
  - target: Vaginal atresia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Meckel diverticulum
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A persistent omphalomesenteric duct remnant, so a midgut developmental
      failure alongside the malrotation.
  - target: Congenital diaphragmatic hernia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Scoliosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Short stature
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reduced growth is recorded in about a third of the cohort. Whether it is a
      primary consequence of the transcriptional defect or secondary to the
      cholestatic and feeding burden is not established.
  - target: Constipation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Plausibly downstream of the enteric malformations rather than a separate
      lesion; the source scores it as a clinical finding without assigning a
      mechanism.
- name: Biliary Dysgenesis
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  description: >-
    Maldevelopment of the biliary tree is the recurrent hepatobiliary lesion,
    reported as biliary atresia, bile-duct paucity, absent gallbladder and
    choledochal cyst across cases. The histological findings are not identical
    between individuals and should not be collapsed into one obligatory lesion.
  cell_types:
  - preferred_term: cholangiocyte
    term:
      id: CL:1000488
      label: cholangiocyte
  - preferred_term: intrahepatic cholangiocyte
    term:
      id: CL:0002538
      label: intrahepatic cholangiocyte
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Here we describe 11 additional individuals with HS, and reinforce the core phenotypes of orofacial clefting, aortic coarctation, genitourinary malformations and biliary dysgenesis"
    explanation: Confirms biliary dysgenesis as a core feature in the largest reported cohort.
  downstream:
  - target: Progressive Cholestatic Liver Injury
    causal_link_type: DIRECT
    description: >-
      Impaired bile flow through a maldeveloped biliary tree produces
      cholestasis.
  - target: Biliary atresia
    causal_link_type: DIRECT
    description: >-
      The severe end of the biliary maldevelopment, presenting as obstructive
      liver disease in infancy.
  - target: Absent gallbladder
    causal_link_type: DIRECT
    description: >-
      Agenesis of the gallbladder as one reported form of the biliary
      maldevelopment.
  - target: Cyst of the ductus choledochus
    causal_link_type: DIRECT
    description: >-
      Choledochal cystic dilatation as another reported form of the biliary
      maldevelopment.
- name: Progressive Cholestatic Liver Injury
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: >-
    Cholestasis presents in the neonatal or infantile period and, in severe
    cases, progresses through ductular change and fibrosis to cirrhosis, portal
    hypertension, variceal bleeding and liver failure requiring transplantation.
    This progression is supported by serial human clinical and biopsy
    observation, but a universal course is not established and some individuals
    remain biochemically affected without progressing.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:18792981
    reference_title: "Hardikar syndrome: new features."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."
    explanation: >-
      Documents the progressive hepatobiliary course reaching transplantation in
      an individual case.
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."
    explanation: >-
      Describes the decompensation sequence. Indirect because this individual's
      MED12 variant remained a variant of uncertain significance, so the case is
      clinically suggestive rather than molecularly confirmed.
  downstream:
  - target: Cholestasis
    causal_link_type: DIRECT
  - target: Hepatic fibrosis
    causal_link_type: DIRECT
  - target: Portal hypertension
    causal_link_type: DIRECT
  - target: Esophageal varix
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Hepatic failure
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Cardiac and Vascular Wall Vulnerability
  biological_scale: ORGANISM
  mechanism_confidence: HYPOTHETICAL
  description: >-
    The 2024 cohort added cardiomyopathy, arrhythmia and non-aortic vascular
    anomalies of the carotid, posterior cerebral, vertebral, pulmonary and renal
    vessels, and the gene-discovery series had already reported a fatal
    unprovoked intracranial hemorrhage at age 21. No mechanism for this arm is
    demonstrated: YAP and TGF-beta are plausible mediators, and the authors also
    allow that the cardiac disease may be independent of both ciliary and YAP
    effects. The node exists so the cardiovascular surveillance recommendation
    has something to attach to, and is marked HYPOTHETICAL accordingly.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein, and renal artery"
    explanation: >-
      Establishes the cardiovascular phenotypes, with the specific arrhythmia
      types and vessels involved.
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We report clinical features of HS with previously undescribed phenotypes, including a fatal unprovoked intracranial hemorrhage at age 21."
    explanation: >-
      A vascular catastrophe in an affected individual. Indirect for this node
      because a single unprovoked hemorrhage does not by itself establish a
      vessel-wall mechanism.
  downstream:
  - target: Cardiomyopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Arrhythmia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Prolonged QT interval
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Ventricular fibrillation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cardiac conduction abnormality
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Arterial aneurysm
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Aneurysmal dilatation of the carotid and posterior cerebral arteries, which with
      the vertebral aneurysm below is the vessel-wall half of this node.
  - target: Vertebral artery aneurysm
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Intracranial hemorrhage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The consequential event the vascular surveillance recommendation exists to
      pre-empt. Reported once in the vascular tabulation and once as a fatal
      unprovoked hemorrhage at age 21.
phenotypes:
- category: Craniofacial
  name: Cleft lip
  phenotype_term:
    preferred_term: Cleft lip
    term:
      id: HP:0410030
      label: Cleft lip
  description: >-
    Orofacial clefting is a core feature. Reported bilaterally in at least one
    case; universal laterality cannot be asserted. The Table 1 `Orofacial
    Clefting` row scores clefting of the lip and palate together at 18/22 (82%),
    which is the category's figure and not cleft lip's, so no band is set here.
  evidence:
  - reference: PMID:18792981
    reference_title: "Hardikar syndrome: new features."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Hardikar syndrome (HS) is a disorder of multiple anomalies predominantly characterized by cleft lip/palate, liver and biliary tract disease, intestinal malrotation, obstructive uropathy, and retinopathy."
    explanation: Lists cleft lip/palate among the defining features.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Orofacial Clefting | − | + | − | + | + | + | − | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 18/22 (82%) |"
    explanation: >-
      Table 1 scores orofacial clefting in 18 of 22 molecularly confirmed females,
      which is the basis for the VERY_FREQUENT band.
- category: Craniofacial
  name: Cleft palate
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
  description: >-
    The Table 1 `Orofacial Clefting` row counts lip and palate clefting together
    at 18/22 (82%). That is the category's figure, not cleft palate's, so no band
    is set here.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Here we describe 11 additional individuals with HS, and reinforce the core phenotypes of orofacial clefting, aortic coarctation, genitourinary malformations and biliary dysgenesis"
    explanation: Reinforces orofacial clefting as a core phenotype in the largest cohort.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Orofacial Clefting | − | + | − | + | + | + | − | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 18/22 (82%) |"
    explanation: >-
      The cohort fraction behind the band: 18 of 22 molecularly confirmed females.
- category: Ophthalmologic
  name: Pigmentary retinopathy
  phenotype_term:
    preferred_term: Cat's paw retinopathy (patchy retinal pigmentation)
    term:
      id: HP:0000580
      label: Pigmentary retinopathy
  description: >-
    Described as a patchy "cat's paw" retinal pigmentation. Retinal pigmentation
    does not imply early visual loss: one reported child retained unaffected
    vision at age four, and longitudinal ophthalmic surveillance is recommended.
    The band is from the Table 1 `Retinal Abnormalities` row. It is kept on this
    phenotype because the patchy pigmentary retinopathy is the only retinal
    feature the source describes for this syndrome, so the row and the finding are
    the same thing here; two of the 22 individuals were not scored.
  frequency: FREQUENT
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Our previously-published HS cohort highlighted core features of HS, including orofacial clefting, aortic coarctation, intestinal malrotation, ectopic ureters, biliary abnormalities, and cat's paw retinopathy (patchy retinal pigmentation)."
    explanation: >-
      Names the characteristic retinal appearance, which is the specificity
      carried in preferred_term above the coarser HPO term.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Retinal Abnormalities | − | + | + | − | Unknown | + | + | − | + | − | − | − | + | + | NA | − | − | + | + | + | + | − | 11/20 (55%) |"
    explanation: >-
      Retinal abnormality scored in 11 of 20 assessed individuals.
- category: Cardiovascular
  name: Coarctation of aorta
  phenotype_term:
    preferred_term: Coarctation of aorta
    term:
      id: HP:0001680
      label: Coarctation of aorta
  description: >-
    No band is set. The Table 1 row scores aortic coarctation or dilation together
    at 15/22 (68%), which is the combined aortic lesion and not coarctation alone.
    Table 2 splits the reported cases into coarctation (10), dilation (5) and
    hypoplasia (1), but those are case counts over the whole reported set rather
    than fractions of the 22-individual cohort, so they cannot be converted into a
    band either. A separate aortic-dilation phenotype was considered and not added:
    HPO has no aortic dilatation term (`runoak -i ols:hp search 'l~aortic
    dilatation'` returns nothing), and `HP:0004942` Aortic aneurysm would assert an
    aneurysm where the source reports dilation.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Hardikar syndrome (HS, OMIM #301068) is an X-linked dominant disorder characterized by cleft lip/palate, pigmentary retinopathy, aortic coarctation, intestinal malrotation, hepatobiliary disease and genitourinary malformations with preserved neurocognition"
    explanation: Lists aortic coarctation among the defining features.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Aortic Coarctation or Dilation | + | + | + | − | + | + | + | + | + | + | − | − | + | − | − | + | + | + | + | − | − | + | 15/22 (68%) |"
    explanation: >-
      The cohort fraction behind the band, scoring coarctation or dilation together
      in 15 of 22 individuals.
- category: Cardiovascular
  name: Cardiomyopathy
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  frequency: FREQUENT
  description: Added to the phenotype by the 2024 cohort; not present in every case.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "With this cohort, we expand the phenotype of HS to include cardiomyopathy, arrhythmia, and vascular defects and we expand the molecular basis of HS to include splice MED12 variants."
    explanation: Reports cardiomyopathy as a newly recognized phenotype.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Cardiomyopathy | + | − | + | − | − | + | + | + | + | − | − | − | − | − | − | − | − | − | − | − | − | − | 7/22 (32%) |"
    explanation: >-
      Cardiomyopathy scored in 7 of 22 individuals, a one-to-one Table 1 row.
- category: Cardiovascular
  name: Arrhythmia
  phenotype_term:
    preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia
  frequency: OCCASIONAL
  description: >-
    Reported as atrial ectopy, ventricular fibrillation and QT prolongation.
    Arrhythmia screening is part of the updated recommended standard of care. The band
    is the figure the paper states for arrhythmia in prose, 3/22 (14%), which maps
    one-to-one onto this phenotype.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein, and renal artery"
    explanation: Names the arrhythmia subtypes observed.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "arrhythmia including atrial ectopy, ventricular fibrillation, and elongated QT interval (3/22; 14%)"
    explanation: The cohort fraction behind the band, stated for arrhythmia specifically.
- category: Cardiovascular
  name: Prolonged QT interval
  phenotype_term:
    preferred_term: Prolonged QT interval
    term:
      id: HP:0001657
      label: Prolonged QT interval
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein, and renal artery"
    explanation: Reports QT prolongation specifically.
- category: Cardiovascular
  name: Ventricular fibrillation
  phenotype_term:
    preferred_term: Ventricular fibrillation
    term:
      id: HP:0001663
      label: Ventricular fibrillation
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein, and renal artery"
    explanation: Reports ventricular fibrillation among the observed arrhythmias.
- category: Gastrointestinal
  name: Intestinal malrotation
  phenotype_term:
    preferred_term: Intestinal malrotation
    term:
      id: HP:0002566
      label: Intestinal malrotation
  description: >-
    Congenital; may present as neonatal intestinal obstruction and require a
    Ladd procedure.
  frequency: FREQUENT
  evidence:
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Hardikar syndrome (MIM 612726) is a rare multiple congenital anomaly syndrome characterized by facial clefting, pigmentary retinopathy, biliary anomalies, and intestinal malrotation, but with preserved cognition."
    explanation: Lists intestinal malrotation among the defining features.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Intestinal Malrotation | + | + | − | − | − | + | − | + | + | − | + | − | + | − | + | − | − | + | + | + | − | − | 11/22 (50%) |"
    explanation: >-
      Intestinal malrotation scored in 11 of 22 individuals.
- category: Gastrointestinal
  name: Cholestasis
  phenotype_term:
    preferred_term: Cholestasis
    term:
      id: HP:0001396
      label: Cholestasis
  description: >-
    Usually neonatal or infantile in onset. Severity ranges from persistent
    biochemical abnormality to progressive jaundice with malnutrition.
  evidence:
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."
    explanation: >-
      Documents the cholestatic course. Indirect because the individual's MED12
      variant remained of uncertain significance.
- category: Gastrointestinal
  name: Biliary atresia
  phenotype_term:
    preferred_term: Biliary atresia
    term:
      id: HP:0005912
      label: Biliary atresia
  description: >-
    No band is set. The Table 1 `Biliary/Gallbladder Malformation` row scores any
    biliary or gallbladder malformation at 16/22 (73%) - atresia, duct paucity,
    absent gallbladder and choledochal cyst together - so that figure is the
    category's and atresia alone is rarer than it.
  evidence:
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Hardikar syndrome (MIM 612726) is a rare multiple congenital anomaly syndrome characterized by facial clefting, pigmentary retinopathy, biliary anomalies, and intestinal malrotation, but with preserved cognition."
    explanation: >-
      Biliary anomalies are a defining feature; biliary atresia is the severe
      reported form.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Biliary/Gallbladder Malformation | − | + | + | − | + | + | + | − | + | + | + | − | + | + | − | + | + | + | + | + | + | − | 16/22 (73%) |"
    explanation: >-
      Biliary or gallbladder malformation scored in 16 of 22 individuals, the cohort
      fraction behind the band.
- category: Gastrointestinal
  name: Absent gallbladder
  phenotype_term:
    preferred_term: Absent gallbladder
    term:
      id: HP:0011467
      label: Absent gallbladder
  description: Rare reported finding, accompanying severe biliary maldevelopment.
  evidence:
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We describe a female infant who presented with progressive cholestatic liver disease and complex hepatobiliary malformations, including an absent gallbladder and paucity of bile ducts, with unremarkable prenatal imaging."
    explanation: >-
      Reports absent gallbladder and bile-duct paucity. Indirect because the
      variant in this individual remained of uncertain significance.
- category: Gastrointestinal
  name: Cyst of the ductus choledochus
  phenotype_term:
    preferred_term: Type 1 choledochal cyst
    term:
      id: HP:0100890
      label: Cyst of the ductus choledochus
  evidence:
  - reference: PMID:18792981
    reference_title: "Hardikar syndrome: new features."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."
    explanation: First report of a type 1 choledochal cyst in this syndrome.
- category: Gastrointestinal
  name: Hepatic fibrosis
  phenotype_term:
    preferred_term: Hepatic fibrosis
    term:
      id: HP:0001395
      label: Hepatic fibrosis
  evidence:
  - reference: PMID:18792981
    reference_title: "Hardikar syndrome: new features."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."
    explanation: >-
      Attests the progressive liver disease that reached transplantation.
      Indirect for fibrosis specifically, which the quoted sentence does not
      name.
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "At 1 month: bile duct proliferation + fibrosis; at 7.5 months: cirrhosis with regenerating nodules + chronic portal inflammation with bile duct proliferation + lobular cholestasis"
    explanation: >-
      Histology naming fibrosis directly, and dating its progression to cirrhosis,
      in the molecularly confirmed 2008 case. This is the direct evidence for
      hepatic fibrosis; the sibling item above attests only the clinical course.
- category: Gastrointestinal
  name: Portal hypertension
  phenotype_term:
    preferred_term: Portal hypertension
    term:
      id: HP:0001409
      label: Portal hypertension
  evidence:
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."
    explanation: >-
      Reports portal hypertension. Indirect because the variant in this
      individual remained of uncertain significance.
- category: Gastrointestinal
  name: Esophageal varix
  phenotype_term:
    preferred_term: Esophageal varix
    term:
      id: HP:0002040
      label: Esophageal varix
  evidence:
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."
    explanation: >-
      Reports esophageal varices. Indirect because the variant in this
      individual remained of uncertain significance.
- category: Gastrointestinal
  name: Hepatic failure
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  description: >-
    Advanced outcome of the progressive hepatobiliary disease; has required
    liver transplantation and has been fatal.
  evidence:
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The clinical course was notable for hepatosplenomegaly, markedly elevated total bile acids, portal hypertension with esophageal varices, and eventual liver failure."
    explanation: >-
      Reports progression to liver failure. Indirect because the variant in this
      individual remained of uncertain significance.
- category: Genitourinary
  name: Hydronephrosis
  phenotype_term:
    preferred_term: Hydronephrosis
    term:
      id: HP:0000126
      label: Hydronephrosis
  description: >-
    No band is set. The Table 1 `Genitourinary Abnormalities` row scores any
    genitourinary malformation at 19/22 (86%), which is the category's figure and
    not this finding's.
  evidence:
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "| GU—hydronephrosis (HP:0000126) | Bilateral | Bilateral | NA | NA | NA | Bilateral | NA | Yes, bilateral | NA |"
    explanation: >-
      Names hydronephrosis directly, bound to the same HPO term, and records it as
      bilateral in four of the compiled individuals. Replaces an earlier citation to
      a sentence that said only "genitourinary malformations".
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Genitourinary Abnormalities | + | + | + | − | + | + | + | + | + | + | + | − | + | + | + | + | + | + | + | + | + | − | 19/22 (86%) |"
    explanation: >-
      The cohort-level fraction the band is taken from: genitourinary abnormality in
      19 of 22 individuals.
- category: Genitourinary
  name: Vesicoureteral reflux
  phenotype_term:
    preferred_term: Vesicoureteral reflux
    term:
      id: HP:0000076
      label: Vesicoureteral reflux
  description: >-
    No band is set. The Table 1 `Genitourinary Abnormalities` row scores any
    genitourinary malformation at 19/22 (86%), which is the category's figure and
    not this finding's.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We previously recommended based on our patient cohort that individuals with HS be screened for orofacial clefting and velopharyngeal insufficiency, retinopathy, congenital heart disease, aortic coarctation, carotid and aortic dilation, cerebral vascular malformations, biliary disease, intestinal malrotation, genitourinary abnormalities, vesicoureteral reflux, and hearing loss."
    explanation: >-
      Vesicoureteral reflux is named as a feature warranting screening in this
      syndrome.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Genitourinary Abnormalities | + | + | + | − | + | + | + | + | + | + | + | − | + | + | + | + | + | + | + | + | + | − | 19/22 (86%) |"
    explanation: >-
      Genitourinary abnormality scored in 19 of 22 individuals, the cohort fraction
      behind the band.
- category: Genitourinary
  name: Ectopic ureteral orifice
  phenotype_term:
    preferred_term: Ectopic ureter
    term:
      id: HP:6000413
      label: Ectopic ureteral orifice
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Our previously-published HS cohort highlighted core features of HS, including orofacial clefting, aortic coarctation, intestinal malrotation, ectopic ureters, biliary abnormalities, and cat's paw retinopathy (patchy retinal pigmentation)."
    explanation: Names ectopic ureters among the core features.
- category: Otologic
  name: Hearing impairment
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  description: >-
    Includes severe bilateral sensorineural loss requiring cochlear
    implantation in at least one reported child.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We previously recommended based on our patient cohort that individuals with HS be screened for orofacial clefting and velopharyngeal insufficiency, retinopathy, congenital heart disease, aortic coarctation, carotid and aortic dilation, cerebral vascular malformations, biliary disease, intestinal malrotation, genitourinary abnormalities, vesicoureteral reflux, and hearing loss."
    explanation: Hearing loss is named as a feature warranting screening in this syndrome.
- category: Craniofacial
  name: Preauricular pit
  phenotype_term:
    preferred_term: Preauricular pit
    term:
      id: HP:0004467
      label: Preauricular pit
  description: >-
    Part of the most frequent feature in the 2024 cohort. No band is set: the Table 1
    `Ears Pits/Tags/Branchial Cleft` row scores preauricular pits, tags and branchial
    cleft anomalies as one category at 17/21 (81%), so that figure is the category's
    and not this individual finding's.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Ears Pits/Tags/Branchial Cleft | + | − | + | + | + | + | + | + | + | − | + | − | + | + | NA | + | + | + | − | + | + | + | 17/21 (81%) |"
    explanation: >-
      Ear pits, tags or branchial cleft anomalies scored in 17 of 21 assessed
      individuals, the highest fraction in the cohort table.
- category: Craniofacial
  name: Preauricular skin tag
  phenotype_term:
    preferred_term: Preauricular tag
    term:
      id: HP:0000384
      label: Preauricular skin tag
  description: >-
    Part of the most frequent feature in the 2024 cohort. No band is set: the Table 1
    `Ears Pits/Tags/Branchial Cleft` row scores preauricular pits, tags and branchial
    cleft anomalies as one category at 17/21 (81%), so that figure is the category's
    and not this individual finding's.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Ears Pits/Tags/Branchial Cleft | + | − | + | + | + | + | + | + | + | − | + | − | + | + | NA | + | + | + | − | + | + | + | 17/21 (81%) |"
    explanation: >-
      Ear pits, tags or branchial cleft anomalies scored in 17 of 21 assessed
      individuals, the highest fraction in the cohort table.
- category: Craniofacial
  name: Branchial anomaly
  phenotype_term:
    preferred_term: Branchial cleft anomaly
    term:
      id: HP:0009794
      label: Branchial anomaly
  description: >-
    Part of the most frequent feature in the 2024 cohort. No band is set: the Table 1
    `Ears Pits/Tags/Branchial Cleft` row scores preauricular pits, tags and branchial
    cleft anomalies as one category at 17/21 (81%), so that figure is the category's
    and not this individual finding's.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Ears Pits/Tags/Branchial Cleft | + | − | + | + | + | + | + | + | + | − | + | − | + | + | NA | + | + | + | − | + | + | + | 17/21 (81%) |"
    explanation: >-
      Ear pits, tags or branchial cleft anomalies scored in 17 of 21 assessed
      individuals, the highest fraction in the cohort table.
- category: Growth
  name: Short stature
  phenotype_term:
    preferred_term: Short stature or small size
    term:
      id: HP:0004322
      label: Short stature
  frequency: OCCASIONAL
  description: >-
    The band is counted from the cells of the Table 1 `Growth` row rather than from its
    total: short stature is named in 3 of the 22 individuals (14%). The row's 8/22 (36%)
    total covers reduced growth as a category, adding four individuals recorded as small
    size and one as low weight, and is not short stature's figure.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Growth | Normal | Normal | Small Size | Small size | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Short stature | Short stature | Normal | Normal | Normal | Normal | Short Stature | Small Size | Low Weight | Small Size | Normal | 8/22 (36%) |"
    explanation: >-
      The row this band is counted from. Short stature is named in 3 of the 22 cells;
      the remaining five of the row's 8/22 total are small size or low weight.
- category: Musculoskeletal
  name: Scoliosis
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  frequency: OCCASIONAL
  description: >-
    The band is counted from the cells of the Table 1 `Musculoskeletal` row rather than
    from its total: scoliosis is named in 3 of the 22 individuals (14%), twice alone and
    once with syndactyly. The row's own 7/22 (32%) total is the musculoskeletal category,
    which also counts digit anomalies, vertebral abnormalities, a sacral dimple and hip
    dysplasia, and is not scoliosis's figure.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Musculoskeletal | − | Scoliosis | − | − | − | − | Scoliosis, syndactyly | Scoliosis | − | − | Sacral dimple | Digit anomalies | Vertebral abnormalities | − | − | − | − | − | − | − | − | Hip dysplasia | 7/22 (32%) |"
    explanation: >-
      The row this band is counted from. Scoliosis appears in 3 of the 22 cells; the
      row's 7/22 total is the whole musculoskeletal category.
- category: Gastrointestinal
  name: Constipation
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Constipation | − | − | + | − | − | + | + | + | + | − | − | − | − | − | NA | − | − | − | − | − | − | + | 6/21 (29%) |"
    explanation: >-
      Constipation scored in 6 of 21 assessed individuals, a one-to-one Table 1 row.
- category: Gastrointestinal
  name: Meckel diverticulum
  phenotype_term:
    preferred_term: Meckel diverticulum
    term:
      id: HP:0002245
      label: Meckel diverticulum
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Meckel’s Diverticulum | − | − | − | − | + | + | − | + | + | − | + | − | − | − | − | − | − | − | − | − | + | − | 6/22 (27%) |"
    explanation: >-
      Meckel's diverticulum scored in 6 of 22 individuals, a one-to-one Table 1 row.
- category: Respiratory
  name: Congenital diaphragmatic hernia
  phenotype_term:
    preferred_term: Congenital diaphragmatic hernia
    term:
      id: HP:0000776
      label: Congenital diaphragmatic hernia
  frequency: OCCASIONAL
  description: >-
    An expanded-phenotype feature rather than a defining one; several cases were
    left-sided.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Diaphragmatic Hernia | − | − | − | + | + | − | + | − | − | − | + | − | − | − | + | − | + | − | − | − | − | − | 6/22 (27%) |"
    explanation: >-
      Diaphragmatic hernia scored in 6 of 22 individuals, a one-to-one Table 1 row.
- category: Cardiovascular
  name: Cardiac conduction abnormality
  phenotype_term:
    preferred_term: Cardiac conduction abnormality
    term:
      id: HP:0031546
      label: Cardiac conduction abnormality
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Cardiac Conduction Abnormalities | − | + | − | − | − | − | − | − | + | − | − | − | − | + | NA | − | − | − | − | − | − | − | 3/21 (14%) |"
    explanation: >-
      Cardiac conduction abnormality scored in 3 of 21 assessed individuals; this is the
      cohort-level counterpart of the arrhythmia subtypes recorded separately.
- category: Cardiovascular
  name: Arterial aneurysm
  phenotype_term:
    preferred_term: Arterial aneurysm (carotid, posterior cerebral, vertebral)
    term:
      id: HP:0002617
      label: Vascular dilatation
  description: >-
    Carotid and posterior cerebral artery aneurysms, one case per vessel in the 2024
    tabulation. The vertebral artery aneurysm from the same table is recorded separately
    below, bound to its own HPO term.

    Bound to the broader `Vascular dilatation` for these two vessels, and the reason is
    per-vessel rather than general. `runoak -i ols:hp search 'l~aneurysm'` returns
    `HP:0034325` Common carotid artery aneurysm, which is declined because the source
    says only "Carotid Artery Aneurysm" without naming the common carotid, and reports a
    left cavernous internal carotid lesion separately - binding the common carotid would
    pick one of the two. For the posterior cerebral artery the same query returns no
    aneurysm term: `HP:0031773` is the posterior *communicating* artery, a different
    vessel, and `runoak -i ols:hp search 'l~posterior cerebral'` returns only
    `HP:0012495` Posterior cerebral artery stenosis, a different lesion. No frequency
    band: the vessel counts are over the whole reported set rather than the
    22-individual cohort.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein, and renal artery"
    explanation: >-
      Names the non-aortic vessels involved, which is what this phenotype records.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Vascular Malformation/Disease | + | − | − | − | − | + | + | + | + | + | − | − | + | − | NA | − | − | − | + | + | − | − | 9/21 (43%) |"
    explanation: >-
      Vascular malformation or disease scored in 9 of 21 assessed individuals. Recorded as
      evidence for the category's presence; no band is set on this narrower finding.
- category: Cardiovascular
  name: Vertebral artery aneurysm
  phenotype_term:
    preferred_term: Vertebral artery aneurysm
    term:
      id: HP:0034179
      label: Vertebral artery aneurysm
  description: >-
    One case in the 2024 vascular tabulation. Recorded separately from the grouped
    carotid and posterior cerebral finding because HPO has an exact term for this
    vessel, which the sibling phenotype's note explains it does not for the other two.
    No frequency band: the vessel counts are over the whole reported set rather than the
    22-individual cohort.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We further expand the phenotype of HS to include arrhythmia (atrial ectopy, ventricular fibrillation, elongated QT interval), cardiomyopathy, and non-aortic vascular anomalies involving most notably the carotid vessels, posterior cerebral artery, vertebral arteries, pulmonary artery and vein, and renal artery"
    explanation: >-
      Names the vertebral arteries among the vessels involved. The Table 2 row for this
      lesion is too short to quote as a snippet on its own.
- category: Cardiovascular
  name: Intracranial hemorrhage
  phenotype_term:
    preferred_term: Intracranial hemorrhage
    term:
      id: HP:0002170
      label: Intracranial hemorrhage
  description: >-
    Reported once in the 2024 vascular tabulation and once as a fatal unprovoked event
    at age 21 in the gene-discovery series. It is the clinical event that makes the
    vascular surveillance recommendation consequential. No frequency band is set from a
    single case.
  evidence:
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We report clinical features of HS with previously undescribed phenotypes, including a fatal unprovoked intracranial hemorrhage at age 21."
    explanation: >-
      A fatal intracranial hemorrhage in an affected young adult.
- category: Genitourinary
  name: Vaginal atresia
  phenotype_term:
    preferred_term: Vaginal atresia
    term:
      id: HP:0000148
      label: Vaginal atresia
  description: >-
    First reported as a new feature in 2008 and since recorded in further molecularly
    confirmed individuals. Covered at cohort level by the Table 1 `Genitourinary
    Abnormalities` row rather than scored separately, so no band is set from it.
  evidence:
  - reference: PMID:18792981
    reference_title: "Hardikar syndrome: new features."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."
    explanation: >-
      The first report of vaginal atresia in this syndrome.
genetic:
- name: MED12
  gene_term:
    preferred_term: MED12
    term:
      id: hgnc:11957
      label: MED12
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  inheritance:
  - name: X-linked Dominant
  notes: >-
    MED12 encodes the scaffold subunit of the Mediator kinase module and sits at
    Xq13.1. The allele class is what assigns a MED12 variant to this disorder
    rather than to the rest of the series: truncating variants in females cause
    Hardikar syndrome, constitutive missense variants cause the male intellectual
    disability syndromes, and somatic missense variants drive uterine leiomyoma.
    A missense variant should not be classified as Hardikar syndrome on
    phenotype alone.

    No ClinGen gene-disease validity assertion is recorded here. ClinGen's
    Definitive assertion for MED12 (CGGV, 2025-10-15) is against
    MONDO:0100000 MED12-related intellectual disability syndrome, which is not
    this entry's disease term and is not an exactMatch mapping of it, so copying
    that tier onto this record would attribute a classification to a pair
    ClinGen did not classify.
  evidence:
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We propose a fifth, female-specific phenotype for MED12, and suggest that nonsense and frameshift loss-of-function MED12 variants in females cause HS."
    explanation: Establishes MED12 as the causative gene for this disorder.
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We performed exome sequencing on two previously reported and five unpublished female patients with a clinical diagnosis of HS."
    explanation: The ascertainment and method behind the gene-disease assignment.
  variants:
  - name: MED12 c.3868-5C>G
    description: >-
      De novo intronic variant reported in an infant with a predominantly
      hepatobiliary presentation. Its predicted splice-acceptor effect was not
      tested at the RNA or protein level and its own authors retained a
      variant-of-uncertain-significance classification, so it is recorded here
      as a candidate allele and not as evidence that splice disruption is an
      established mechanism.
    clinical_significance: UNCERTAIN_SIGNIFICANCE
    gene:
      preferred_term: MED12
      term:
        id: hgnc:11957
        label: MED12
    evidence:
    - reference: PMID:42510827
      reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "WES identified a novel de novo intronic heterozygous variant in MED12 (c.3868-5C>G)."
      explanation: Reports the variant and its de novo heterozygous status.
    - reference: PMID:42510827
      reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "The identified MED12 variant is classified as a variant of uncertain significance (VUS)."
      explanation: >-
        The authors' own classification, which is why this entry does not treat
        the allele as pathogenic.
animal_models:
- name: Cardiac-specific Med12 deletion mouse
  species: Mouse
  genotype: Cardiac-specific Med12 deletion
  publication: PMID:39045790
  description: >-
    Cited in the 2024 Hardikar cohort as supporting evidence that MED12 loss can
    produce cardiac disease. Recorded because it is the only model evidence
    bearing on the cardiovascular arm of this syndrome.
  modeled_mechanisms:
  - target: Cardiac and Vascular Wall Vulnerability
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: ORGANISM
    description: >-
      Shows that tissue-restricted Med12 loss is sufficient for cardiomyopathy in
      mouse.
    limitations: >-
      A cardiac-restricted conditional deletion is not the human genotype, which
      is a constitutive heterozygous truncating allele on one X chromosome
      subject to X-inactivation. The model speaks to cardiomyopathy alone and not
      to the arrhythmia or extracardiac vascular anomalies, and this entry cites
      it only through the 2024 paper's summary rather than from the primary
      report.
    divergences:
    - divergence_type: POPULATION_MISMATCH
      materiality: QUALIFYING
      description: >-
        Homozygous tissue-restricted deletion in mouse against constitutive
        heterozygous truncation with skewed X-inactivation in human females; the
        dosage and its mosaicism across tissues are not comparable.
    - divergence_type: BOUNDARY_OMISSION
      materiality: QUALIFYING
      description: >-
        The model is restricted to heart, so the vascular anomalies of the
        carotid, cerebral, vertebral, pulmonary and renal vessels reported in
        patients are outside it entirely.
    evidence:
    - reference: PMID:39045790
      reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      quote_role: BACKGROUND
      snippet: "Of note, cardiac-specific MED12 deletion in mice caused dilated cardiomyopathy and a missense MED12 variant was identified in an individual with dilated cardiomyopathy"
      explanation: >-
        The model result as reported in the Hardikar cohort paper. Graded
        BACKGROUND because that paper is restating two prior studies rather than
        reporting its own mouse work.
treatments:
- name: Ladd Procedure
  description: >-
    Surgical correction of intestinal malrotation, performed in a reported case
    presenting with neonatal obstruction.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Ladd procedure
    term:
      id: NCIT:C168307
      label: Ladd Procedure
  target_phenotypes:
  - preferred_term: Intestinal malrotation
    term:
      id: HP:0002566
      label: Intestinal malrotation
  evidence:
  - reference: PMID:18792981
    reference_title: "Hardikar syndrome: new features."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Hardikar syndrome (HS) is a disorder of multiple anomalies predominantly characterized by cleft lip/palate, liver and biliary tract disease, intestinal malrotation, obstructive uropathy, and retinopathy."
    explanation: >-
      Establishes intestinal malrotation as a feature of the syndrome, which is what
      this operation addresses. Indirect because the quoted sentence names the
      malformation and not the operation; the abstract does not name the procedure,
      which is why no stronger quote is attached.
- name: Liver Transplantation
  description: >-
    Performed for end-stage liver disease arising from the progressive
    cholestatic course. Jaundice resolved and growth improved after
    transplantation in the reported case, while urinary infections recurred.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: liver transplantation
    term:
      id: NCIT:C15271
      label: Liver Transplantation
  target_mechanisms:
  - target: Progressive Cholestatic Liver Injury
    description: >-
      Replaces the failing organ; does not address the extrahepatic congenital
      malformations.
  evidence:
  - reference: PMID:18792981
    reference_title: "Hardikar syndrome: new features."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "New features, hitherto not reported, were vaginal atresia, a type 1 choledochal cyst and, owing to the progressive nature of the liver disease, the need for liver transplantation."
    explanation: Documents the need for liver transplantation in this syndrome.
diagnosis:
- name: Trio exome or genome sequencing covering MED12
  description: >-
    Molecular diagnosis rests on sequencing that covers MED12 with parental
    segregation, interpreted against variant class, phenotype and possible
    mosaicism. The assay needs to reach splice-region changes and copy-number
    variation: the 2024 cohort extended the allele class to splice-site variants,
    and an intragenic MED12 deletion has been reported, so a normal sequencing
    result on a limited assay does not exclude the diagnosis.
  evidence:
  - reference: PMID:33244166
    reference_title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We performed exome sequencing on two previously reported and five unpublished female patients with a clinical diagnosis of HS."
    explanation: The method by which the molecular diagnosis was established in the gene-discovery series.
- name: Cardiac, arrhythmia and vascular surveillance
  description: >-
    Regular cardiac imaging, arrhythmia screening and vascular imaging, added to
    the recommended standard of care by the 2024 cohort on the strength of the
    newly recognized cardiomyopathy, arrhythmia and non-aortic vascular
    anomalies. The source states three specific schedules: an annual echocardiogram
    for cardiomyopathy, a lifelong annual EKG with 24-hour Holter monitor for
    arrhythmia, and a baseline total-body MRA with and without gadolinium repeated at
    least every two years for vascular malformations, with later scans done without
    gadolinium if the baseline is normal. These are case-series expert
    recommendations, not prospectively validated intervals.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Our data support updating HS standard-of-care to include regular cardiac imaging, arrhythmia screening, and vascular imaging."
    explanation: The surveillance recommendation and the cohort data behind it.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Based on our expanded cohort and recent reports, we additionally recommend 1) annual echocardiogram to screen for cardiomyopathy, 2) lifelong annual EKG and 24-hour Holter monitor to screen for arrhythmia, and 3) baseline total body MRA with and without contrast (gadolinium) with repeat imaging at least every 2 years to screen for global vascular malformations"
    explanation: >-
      The three specific surveillance schedules the cohort recommends, with their
      intervals. An earlier version of this entry said the source gave no interval;
      this is the sentence that shows it does.
  notes: >-
    Filed under diagnosis rather than treatments because echocardiography,
    arrhythmia monitoring and vascular imaging are diagnostic procedures. The
    cost of filing it here is that `Diagnosis` has no `target_mechanisms`, so the
    link to the `Cardiac and Vascular Wall Vulnerability` pathophysiology node
    that motivates the surveillance is stated in prose rather than carried as an
    edge.
- name: Multisystem evaluation at diagnosis
  description: >-
    The 2024 cohort's recommended workup spans the organ systems the syndrome
    malforms: orofacial clefting and velopharyngeal insufficiency, retinopathy,
    congenital heart disease and aortic coarctation, carotid and aortic dilation,
    cerebral vascular malformations, biliary disease, intestinal malrotation,
    genitourinary abnormalities, vesicoureteral reflux and hearing loss.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "We previously recommended based on our patient cohort that individuals with HS be screened for orofacial clefting and velopharyngeal insufficiency, retinopathy, congenital heart disease, aortic coarctation, carotid and aortic dilation, cerebral vascular malformations, biliary disease, intestinal malrotation, genitourinary abnormalities, vesicoureteral reflux, and hearing loss."
    explanation: The recommended multisystem evaluation, as stated by the cohort that proposed it.
differential_diagnoses:
- name: Alagille syndrome
  description: >-
    Shares cholestasis, cardiac and ocular involvement. The 2008 report
    speculated that the two conditions might be genetically related on the
    strength of that overlap; no JAG1 or NOTCH2 lesion has been demonstrated in
    Hardikar syndrome, and the speculation predates the identification of MED12.
  evidence:
  - reference: PMID:18792981
    reference_title: "Hardikar syndrome: new features."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "It is intriguing to speculate, that HS could be genetically related to Alagille syndrome (AS), since both conditions share an unusual number of phenotypic abnormalities."
    explanation: >-
      The source of the Alagille comparison, quoted so that its status as
      explicit speculation is visible in the entry.
- name: MED12-related intellectual disability syndrome
  description: >-
    The hemizygous male arm of the MED12 series (FG/Opitz-Kaveggia, Lujan,
    X-linked Ohdo), caused by recurrent missense alleles and dominated by
    intellectual disability. Hardikar syndrome is distinguished by truncating
    alleles, female sex, and characteristically preserved neurocognition.
  disease_term:
    preferred_term: MED12-related intellectual disability syndrome
    term:
      id: MONDO:0100000
      label: MED12-related intellectual disability syndrome
  distinguishing_features:
  - Truncating (nonsense, frameshift, splice) MED12 alleles, versus recurrent missense alleles in the male syndromes.
  - Affected individuals are female; the male syndromes affect hemizygous males.
  - Neurocognition is characteristically preserved, where intellectual disability defines the male syndromes.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "This contrasts to HS, which is caused predominantly by nonsense/frameshift MED12 variants and is characterized by normal neurocognition"
    explanation: States the allele-class and cognitive distinction between the two arms.
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "| Development | Normal | Normal | Normal | Normal | Unknown | Normal |  | Normal | Normal | Normal | Mild delay (medical complexity) | Developmental Delay | Normal | Normal | NA | Normal | Normal | Normal | Normal | Normal | Normal | Normal | 1/20 (5%) |"
    explanation: >-
      The cohort measurement behind "preserved neurocognition", and the strongest
      evidence for the distinction this differential rests on: development was
      scored abnormal in only 1 of 20 assessed individuals, and that individual is
      annotated as having medical complexity. This is the direct counterpart to the
      BACKGROUND sentences elsewhere in the entry that assert preserved cognition.
discussions:
- discussion_id: hardikar_med12_hedgehog_direction
  prompt: >-
    Does MED12 promote or inhibit Hedgehog signaling, and does the answer depend
    on whether the cell is ciliated?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Hedgehog Pathway Activation
  rationale: >-
    The 2024 Hardikar cohort found that MED12 knockdown abolishes
    agonist-induced GLI1 induction, which makes MED12 a positive regulator of
    Hedgehog signaling. Earlier work reported the opposite, that MED12 inhibits
    Hedgehog, and the authors flag the contradiction themselves rather than
    leaving it implicit. Their proposed explanations are that their experiments
    were performed in serum-free conditions in which cells are ciliated, and
    that MED12 may have a cilium-independent effect on Hedgehog that the earlier
    studies measured and theirs did not.

    This is not only an external disagreement. dismech already encodes the
    inhibitory direction for a different MED12 allele: the FG syndrome entry
    carries a pathophysiology node for derepression of GLI3-dependent Sonic
    Hedgehog target transcription, which asserts that MED12 normally restrains
    Hedgehog output. Both entries may be right, because the alleles differ -
    FG syndrome is the recurrent p.R961W missense that impairs MED12-CDK8
    association, while this entry's alleles are truncating - but the two
    directions should not be asserted side by side in the knowledge base without
    the tension being recorded. Resolving it bears on whether the two arms of the
    MED12 series share a mechanism or merely a gene.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "This contrasts with our data, which suggests that MED12 promotes hedgehog signaling."
    explanation: >-
      The authors' statement of the disagreement, immediately after noting the
      prior reports that MED12 inhibits Hedgehog signaling.
- discussion_id: hardikar_organ_specific_lesion
  prompt: >-
    Which cell types lose primary cilia, Hedgehog output or YAP/TEAD output in
    each affected organ, and when during development?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Disrupted Developmental Organogenesis
  rationale: >-
    Every molecular measurement behind this entry's mechanism was made in a
    retinal pigment epithelial cell line by siRNA knockdown. That establishes
    that MED12 loss reduces ciliation and Hedgehog and YAP output in a cell, and
    it does not establish which of the malformed organs each defect accounts
    for, nor whether the relevant window is the same for the biliary tree, the
    palate, the retina and the aorta. There is no patient-cell atlas for this
    syndrome, and no patient-derived line has been profiled. The authors
    themselves name the experiment that would close this: interrogation of
    ciliogenesis and YAP signaling, with unbiased transcriptomics and proteomics,
    in fibroblast lines from unaffected relatives, individuals with Hardikar
    syndrome, and individuals with MED12-related intellectual disability.
  evidence:
  - reference: PMID:39045790
    reference_title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: "To evaluate a role for MED12 in ciliogenesis, retinal pigment epithelial (RPE) cells, an established cell model for the study of ciliopathy-spectrum disease, were serum starved for 24 hours to promote ciliogenesis or were grown in complete medium (control) and MED12 expression was evaluated by quantitative PCR (qPCR)."
    explanation: >-
      Names the single cell system the mechanism rests on, which is what makes
      the organ-level assignment a gap.
- discussion_id: hardikar_xci_tissue_distribution
  prompt: >-
    In which affected organs does X-inactivation skewing favour the intact MED12
    allele, and does the direction of skewing explain why some individuals
    present with liver disease alone?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Extremely Skewed X-Chromosome Inactivation
  rationale: >-
    Skewed X-inactivation was found in every informatively tested individual, so
    it is a real and consistent feature rather than an incidental one. What it
    cannot do, measured in blood, is say which allele is active in liver,
    retina, palate or aorta. This matters for a specific clinical observation:
    at least one reported infant presented with severe hepatobiliary disease and
    few other anomalies, which organ-specific skewing is an obvious candidate to
    explain and which nothing currently tests. Settling it needs allele-specific
    expression in affected tissue, which for most of these organs means
    post-mortem or explant material.
  evidence:
  - reference: PMID:42510827
    reference_title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Unlike most previously reported cases, the predominant and early manifestation in our case was severe hepatobiliary disease with limited additional anomalies, suggesting possible phenotypic variability within the MED12-related Hardikar syndrome spectrum."
    explanation: >-
      The organ-restricted presentation this gap is about. Indirect because the
      individual's variant remained of uncertain significance and because the
      report does not test X-inactivation as the explanation.
review_notes: >-
  Curated 2026-10-09 from an Edison (falcon) deep-research report plus direct
  reading of the primary sources. The report is committed at
  research/Hardikar_Syndrome-deep-research-falcon.md; `just preflight-dr`
  against MONDO:0012997 returned PASS, with MED12 the dominant gene mention and
  the OMIM sets overlapping on 301068.

  The report stated that Strong et al. 2024 "was identified bibliographically
  but its primary text could not be examined here; no experimental results are
  attributed to it below." That paper (PMID:39045790) turned out to be the
  principal mechanistic source for this disease - it is where the ciliation,
  Hedgehog and YAP results come from, along with the cardiomyopathy, arrhythmia
  and vascular phenotypes and the splice-variant extension - so it was fetched
  and read directly, and most of this entry's mechanism rests on it rather than
  on the report. The report's own mechanism section, built from older zebrafish
  and mouse Med12 work on endoderm specification and Wnt/SOX9 signalling, is
  not curated here: it is model-organism evidence for MED12 developmental
  biology in general, and the human cell-based ciliary and YAP results are both
  more specific to this disease and more recent.

  Every ontology identifier in this entry was looked up in the step it was
  written. HP:0100890 is worth flagging: the research report called it
  "Choledochal cyst" and HPO's canonical label is "Cyst of the ductus
  choledochus", so the binding is right and the report's label would have
  failed validation. HP:6000413 Ectopic ureteral orifice was similarly checked
  rather than assumed from the phrase "ectopic ureters".

  Two bindings were declined on positive grounds and the reasoning is recorded
  on the nodes themselves rather than here: GO:0035329 hippo signaling on the
  YAP node, because that term names the kinase cascade that inhibits YAP and
  would invert the claim, and any ontology term at all on the X-inactivation
  node.

  All 31 candidate snippets were verified as exact substrings of the cached
  references before any YAML was written.

  Review round 2. The round-1 fix over-corrected: bands derived from Table 1
  category rows were attached to individual findings, which made the slot assert
  of one finding what the source establishes only for its category. Those bands
  are removed, two are recounted from the row cells (scoliosis and short stature,
  3 of 22 each, against category totals of 32% and 36%), and the rule now in the
  notes above distinguishes the three cases. A description caveat does not reach
  anything that reads the `frequency` slot, which is the point I had missed.

  Two further round-2 corrections, both of the same false-absence kind as the
  round-1 one. The surveillance entry said the source gave no screening interval;
  it gives three, in the same paragraph as the sentence already quoted, and they
  are now stated and cited. And the `Arterial aneurysm` note claimed HPO's
  aneurysm terms were all vessel-mismatched, citing a query that in fact returns
  `HP:0034179` Vertebral artery aneurysm - an exact match for one of the three
  vessels. That vessel now has its own phenotype, and the note explains per
  vessel why `HP:0034325` is declined for the carotid and why no posterior
  cerebral artery aneurysm term exists.

  Review round 1. The first version of this entry said phenotype frequencies
  could not be given because every available count was a literature compilation
  rather than a denominator. That was wrong, and wrong about a source already
  cached and already read: Table 1 of PMID:39045790 scores every phenotype across
  22 molecularly confirmed females and prints a fraction on each row. The entry
  now carries `frequency` bands taken from that table, each with its row quoted as
  evidence, and eleven phenotypes that table and Table 2 report and the first
  version omitted - preauricular pits, preauricular tags, branchial anomaly, short
  stature, scoliosis, constipation, Meckel diverticulum, congenital diaphragmatic
  hernia, cardiac conduction abnormality, arterial aneurysm and intracranial
  hemorrhage - plus vaginal atresia, which appears in a 2008 sentence the entry
  was already quoting for something else.

  Where a Table 1 row scores a category rather than a single finding, the band is
  recorded on the phenotypes making up that category and each description says the
  fraction is the category's. No band is derived from Table 2, whose vessel counts
  are over the whole reported set rather than the 22-individual cohort.

  Two other corrections from the same round. Liver transplantation was bound to
  NCIT:C15289 Organ Transplantation with a note admitting the specific term had not
  been looked up; it is now NCIT:C15271 Liver Transplantation. And the
  cardiovascular surveillance entry, filed under `treatments` with a note claiming
  that was the only structural home in the schema, has moved to `diagnosis`, which
  exists and is where diagnostic procedures belong - the note was a false statement
  about the schema.

  One self-caught error worth recording, because it is the same shape as the
  denominator mistake. The Ladd procedure treatment added in this round was first
  written with a generic `NCIT:C15329` binding and a note asserting that
  `runoak -i ols:ncit search 'l~Ladd'` returns nothing. Running that query returns
  `NCIT:C168307` Ladd Procedure, so the note was false and the binding
  unnecessarily broad. Both are corrected; the lesson is that a negative-existence
  note is only worth writing after the search it cites has actually been run.
references:
- reference: PMID:39045790
  title: Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.
- reference: PMID:33244166
  title: De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.
- reference: PMID:18792981
  title: "Hardikar syndrome: new features."
- reference: PMID:42510827
  title: "A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review."
- reference: PMID:33925166
  title: "MED12-Related (Neuro)Developmental Disorders: A Question of Causality."

📚

References & Deep Research

References

5

PMID:39045790

Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.

No top-level findings curated for this source.

PMID:33244166

De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.

No top-level findings curated for this source.

PMID:18792981

Hardikar syndrome: new features.

No top-level findings curated for this source.

PMID:42510827

A Novel Intronic Variant in MED12 Associated with a Predominantly Hepatobiliary Phenotype Suggestive of Hardikar Syndrome: A Case Report and Literature Review.

No top-level findings curated for this source.

PMID:33925166

MED12-Related (Neuro)Developmental Disorders: A Question of Causality.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record review notes

Curated 2026-10-09 from an Edison (falcon) deep-research report plus direct reading of the primary sources. The report is committed at research/Hardikar_Syndrome-deep-research-falcon.md; `just preflight-dr` against MONDO:0012997 returned PASS, with MED12 the dominant gene mention and the OMIM sets overlapping on 301068. The report stated that Strong et al. 2024 "was identified bibliographically but its primary text could not be examined here; no experimental results are attributed to it below." That paper (PMID:39045790) turned out to be the principal mechanistic source for this disease - it is where the ciliation, Hedgehog and YAP results come from, along with the cardiomyopathy, arrhythmia and vascular phenotypes and the splice-variant extension - so it was fetched and read directly, and most of this entry's mechanism rests on it rather than on the report. The report's own mechanism section, built from older zebrafish and mouse Med12 work on endoderm specification and Wnt/SOX9 signalling, is not curated here: it is model-organism evidence for MED12 developmental biology in general, and the human cell-based ciliary and YAP results are both more specific to this disease and more recent. Every ontology identifier in this entry was looked up in the step it was written. HP:0100890 is worth flagging: the research report called it "Choledochal cyst" and HPO's canonical label is "Cyst of the ductus choledochus", so the binding is right and the report's label would have failed validation. HP:6000413 Ectopic ureteral orifice was similarly checked rather than assumed from the phrase "ectopic ureters". Two bindings were declined on positive grounds and the reasoning is recorded on the nodes themselves rather than here: GO:0035329 hippo signaling on the YAP node, because that term names the kinase cascade that inhibits YAP and would invert the claim, and any ontology term at all on the X-inactivation node. All 31 candidate snippets were verified as exact substrings of the cached references before any YAML was written. Review round 2. The round-1 fix over-corrected: bands derived from Table 1 category rows were attached to individual findings, which made the slot assert of one finding what the source establishes only for its category. Those bands are removed, two are recounted from the row cells (scoliosis and short stature, 3 of 22 each, against category totals of 32% and 36%), and the rule now in the notes above distinguishes the three cases. A description caveat does not reach anything that reads the `frequency` slot, which is the point I had missed. Two further round-2 corrections, both of the same false-absence kind as the round-1 one. The surveillance entry said the source gave no screening interval; it gives three, in the same paragraph as the sentence already quoted, and they are now stated and cited. And the `Arterial aneurysm` note claimed HPO's aneurysm terms were all vessel-mismatched, citing a query that in fact returns `HP:0034179` Vertebral artery aneurysm - an exact match for one of the three vessels. That vessel now has its own phenotype, and the note explains per vessel why `HP:0034325` is declined for the carotid and why no posterior cerebral artery aneurysm term exists. Review round 1. The first version of this entry said phenotype frequencies could not be given because every available count was a literature compilation rather than a denominator. That was wrong, and wrong about a source already cached and already read: Table 1 of PMID:39045790 scores every phenotype across 22 molecularly confirmed females and prints a fraction on each row. The entry now carries `frequency` bands taken from that table, each with its row quoted as evidence, and eleven phenotypes that table and Table 2 report and the first version omitted - preauricular pits, preauricular tags, branchial anomaly, short stature, scoliosis, constipation, Meckel diverticulum, congenital diaphragmatic hernia, cardiac conduction abnormality, arterial aneurysm and intracranial hemorrhage - plus vaginal atresia, which appears in a 2008 sentence the entry was already quoting for something else. Where a Table 1 row scores a category rather than a single finding, the band is recorded on the phenotypes making up that category and each description says the fraction is the category's. No band is derived from Table 2, whose vessel counts are over the whole reported set rather than the 22-individual cohort. Two other corrections from the same round. Liver transplantation was bound to NCIT:C15289 Organ Transplantation with a note admitting the specific term had not been looked up; it is now NCIT:C15271 Liver Transplantation. And the cardiovascular surveillance entry, filed under `treatments` with a note claiming that was the only structural home in the schema, has moved to `diagnosis`, which exists and is where diagnostic procedures belong - the note was a false statement about the schema. One self-caught error worth recording, because it is the same shape as the denominator mistake. The Ladd procedure treatment added in this round was first written with a generic `NCIT:C15329` binding and a note asserting that `runoak -i ols:ncit search 'l~Ladd'` returns nothing. Running that query returns `NCIT:C168307` Ladd Procedure, so the note was false and the binding unnecessarily broad. Both are corrected; the lesson is that a negative-existence note is only worth writing after the search it cites has actually been run.

Create: Hardikar Syndrome (MONDO:0012997, MED12) · 2026-10-09T20:27:40Z · View source

Created the entry for Hardikar syndrome, the female-specific truncating-allele arm of the MED12 series and the last uncurated MED12 disease. Closes the stub Cholestasis-pigmentary_Retinopathy-cleft_Palate_Syndrome.yaml, which is deleted in the same change. Claim issue #13793. Naming. Curated as Hardikar_Syndrome rather than the stub's proposed_name (Cholestasis-pigmentary_Retinopathy-cleft_Palate_Syndrome, MONDO's label). The eponym is what the primary literature uses and what the existing MED12 has_subtypes row on Mediator_Complex_Neurodevelopmental_Disorder already calls it. MONDO's label is retained as the disease_term label and as a synonym. Sources and how they were used. Deep research was run with Edison/falcon (research/Hardikar_Syndrome-deep-research-falcon.md, 21.6 min, committed with its citations sidecar and artifacts). just preflight-dr against MONDO:0012997 returned PASS: MED12 was the dominant gene mention at 35, and the report's OMIM set overlapped MONDO's on 301068. The report's own reference validation recorded 10/10 resolved with a 0.0 confabulation rate and zero off-topic, and its term validation 15/15 resolved; its single reported label mismatch is an artifact of the template text 'MONDO:0012997 (if available)' being parsed as a label. The report stated plainly that Strong et al. 2024 'was identified bibliographically but its primary text could not be examined here; no experimental results are attributed to it below.' That paper, PMID:39045790, turned out to be the principal mechanistic source for the disease, so it was fetched and read directly. It supplies the ciliation, Hedgehog and YAP/TEAD results, the cardiomyopathy/arrhythmia/vascular phenotypes, the extension of the allele class to splice-site variants, and the surveillance recommendation. Most of this entry's mechanism therefore rests on a source the research report explicitly did not read. The report's own mechanism section, assembled from older zebrafish and mouse Med12 work on endoderm specification and Wnt/SOX9 signalling, was deliberately not curated. It is model-organism evidence about MED12 developmental biology in general rather than about this disease, and the human cell-based ciliary and YAP results are both more specific and more recent. This is a decision not to use available DR content, not an oversight. Pathograph. Eleven nodes running from MED12 truncating loss of function through reduced dosage in the Mediator kinase module to three parallel molecular defects (impaired primary ciliogenesis, impaired Hedgehog pathway activation, impaired YAP-TEAD transcriptional output), converging on disrupted developmental organogenesis and then branching to biliary dysgenesis with progressive cholestatic liver injury and to a cardiac/vascular arm. Skewed X-inactivation is modelled as a separate node feeding dosage, because it is a measured and consistent finding but is measured in blood and so cannot say which allele is active in an affected organ. mechanism_confidence is graded per node: ESTABLISHED for the human genetics and the in vitro molecular results, PROVISIONAL for the organogenesis node whose authors state it as a model, HYPOTHETICAL for the cardiac/vascular node where the authors allow that the cardiac disease may be independent of both ciliary and YAP effects. Verified connectivity with dismech.graph.build_causal_graph: 39 edges over 36 nodes, orphan_targets empty, no isolated nodes. An initial pass left Biliary atresia, Absent gallbladder and Cyst of the ductus choledochus unwired; they were connected downstream of Biliary Dysgenesis, where they belong. just list-disconnected-phenotypes now reports 21 of 21 phenotypes causally connected. Ontology bindings. Every identifier was looked up in the step it was written. HP:0100890 is the one to note: the research report called it 'Choledochal cyst' while HPO's canonical label is 'Cyst of the ductus choledochus', so the binding was right and the report's label would have failed validation. HP:6000413 Ectopic ureteral orifice was checked rather than inferred from the phrase 'ectopic ureters'; HP:0000070, which a careless search would have returned, is Ureterocele and is not it. Two bindings were declined on positive grounds, with the reasoning recorded on the nodes. GO:0035329 hippo signaling was rejected for the YAP node because that term denotes the Hippo kinase cascade, which inhibits YAP, so binding it with a DECREASED modifier would assert the opposite of the source; searched l~Hippo, l~TEAD and l~transcription coactivator activity, and GO has no biological-process term for YAP/TEAD-driven transcription, so the process slot carries GO:0006357 with the specific claim in preferred_term and the YAP/TEAD identity kept queryable through the GO:0140552 TEAD-YAP complex component. The X-inactivation node carries no term at all, because HPO's inheritance subtree has no term for skewed X-inactivation as a cellular state and the GO X-inactivation terms describe the normal process, so a modifier would assert a defect in the inactivation machinery that no source claims. Deliberate restraint on the 2026 case report. PMID:42510827 is cited for phenotypic observations and for the existence of its candidate allele only. Its MED12 c.3868-5C>G variant was retained as a variant of uncertain significance by its own authors with no RNA or protein validation, so it is recorded with clinical_significance UNCERTAIN_SIGNIFICANCE, is not counted as a molecularly confirmed case, and is not used as evidence that splice disruption is an established mechanism. Every evidence item drawn from that report is graded directness INDIRECT for that reason. No ClinGen gene-disease validity assertion was recorded, and the reason is in the genetic notes: ClinGen's Definitive MED12 assertion is against MONDO:0100000 MED12-related intellectual disability syndrome, which is neither this entry's disease_term nor an exactMatch mapping of it, so copying that tier here would attribute a classification to a pair ClinGen did not classify. Three discussions. hardikar_med12_hedgehog_direction is a CONTROVERSY recording that this entry asserts MED12 promotes Hedgehog signalling while dismech's own FG_Syndrome_1 entry carries a node for derepression of GLI3-dependent Sonic Hedgehog target transcription, which asserts the opposite. Both may be correct because the alleles differ, but the tension should be recorded rather than left for a reader to find. The other two are KNOWLEDGE_GAPs: that the whole molecular mechanism rests on siRNA knockdown in one retinal pigment epithelial line with no organ-level assignment, and that X-inactivation skewing is untested as the explanation for the organ-restricted hepatobiliary presentation. Prevalence is recorded as CASES_IN_LITERATURE / ULTRA_RARE with no numeric rate, and no phenotype carries a frequency band, because every available count is a literature compilation rather than a denominator. Validation, all run in this worktree and read: just validate (54 snippets checked, 59 titles checked, 0 issues), just validate-terms (passed), just check-entity-refs, just check-causal-targets, just check-duplicate-keys, just check-qualifier-terms, just check-stubs (no errors after the stub deletion), just model-scale-audit (1 link, scale ALIGNED, 2 typed divergences, confirming the audit can see the link rather than reporting zero). All 31 candidate snippets were verified as exact substrings of the cached references before any YAML was written. Review round 1 (ai4c-reviewer, CHANGES_REQUESTED on 4c980ddb). All four blocking items accepted; the central one was a false claim of mine. The entry, its prevalence notes and its PR body all said phenotype frequencies could not be given because every available count was a literature compilation rather than a denominator. That is false, and false about a source this entry already cites and I had already read: Table 1 of PMID:39045790 scores each phenotype across 22 molecularly confirmed females and prints a fraction on every row, at lines 176-191 of the cached record. This is the same shape as the negative-existence failures CLAUDE.md warns about - an unchecked absence claim that reads as diligence and tells the next reader not to look. Corrected by adding frequency bands from that table, each carrying its own table row as a quoted evidence item, and by adding the phenotypes the first version omitted: preauricular pit, preauricular skin tag, branchial anomaly, short stature, scoliosis, constipation, Meckel diverticulum, congenital diaphragmatic hernia, cardiac conduction abnormality, arterial aneurysm, intracranial hemorrhage and vaginal atresia. Phenotype count goes 21 to 33, all 33 causally connected; the new structural features wire from Disrupted Developmental Organogenesis and the vascular ones from Cardiac and Vascular Wall Vulnerability. Edges 39 to 51. Band policy, stated in the entry notes rather than left implicit: where a Table 1 row scores a category rather than one finding, the band is recorded on the phenotypes composing that category and each description says the fraction is the category's. No band is taken from Table 2, whose vessel counts are over the whole reported set rather than the 22-individual cohort. The Development row, 1/20 abnormal, is now the direct evidence for preserved neurocognition on the MED12 differential, replacing reliance on BACKGROUND sentences. Item 3: liver transplantation rebound from NCIT:C15289 Organ Transplantation to NCIT:C15271 Liver Transplantation. The reviewer supplied that CURIE and it was checked rather than taken on trust - it is in cache/ncit/terms.csv with that exact canonical label and three other disorder entries already bind it. The note that justified the broad binding by admitting the specific term had not been looked up is deleted; under the term contract that note was an instruction to go and look it up. Item 4: the cardiovascular surveillance entry has moved from treatments to a new diagnosis block, together with the trio-sequencing route and the multisystem evaluation the 2024 cohort recommends. Its note had claimed treatments was the only structural home in the schema for it, which is false: Disease.diagnosis exists with range Diagnosis. The cost of moving it is that Diagnosis has no target_mechanisms, so the link to the Cardiac and Vascular Wall Vulnerability node is now prose; that trade-off is recorded on the entry rather than hidden. Suggestions taken: hepatic fibrosis now carries DIRECT histology evidence from the molecularly confirmed 2008 case rather than resting on a sentence that never named fibrosis; hydronephrosis now cites a row that names it and binds the same HPO term, replacing a quote that said only "genitourinary malformations"; and a Ladd procedure treatment links to intestinal malrotation. One error I made inside this round and caught myself, recorded because it is the same shape as the blocking one. The Ladd treatment was first written with a generic NCIT:C15329 Surgical Procedure binding and a note asserting that `runoak -i ols:ncit search 'l~Ladd'` returns nothing. Running that query returns NCIT:C168307 Ladd Procedure. The note was false and the binding needlessly broad; both are fixed, and NCIT:C168307 passes term validation, so it is inside the TreatmentTerm enum. Re-validated after the round: just validate 81 snippets / 86 titles / 0 issues; just validate-disorders passed; validate-terms passed; check-entity-refs, check-causal-targets, check-duplicate-keys, check-qualifier-terms clean; list-disconnected-phenotypes 33/33 connected. Every new snippet, including all 16 Table 1 rows, was verified as an exact substring before being written. Review round 2 (ai4c-reviewer, CHANGES_REQUESTED, submitted twice on 3b5e5aa5 seventeen seconds apart - one set of findings, not two). Three items, all accepted. The round-1 fix over-corrected, and the reviewer said so plainly about their own request: bands derived from Table 1 *category* rows had been attached to individual findings, so the slot asserted of one finding what the source establishes only for its category. 86% of patients did not have hydronephrosis; that is the figure for any genitourinary anomaly. A description caveat does not reach anything that reads `frequency`, which is the part I had wrong. Bands removed from cleft lip, cleft palate, the three ear findings, hydronephrosis, vesicoureteral reflux, biliary atresia and aortic coarctation; their category fractions stay in the descriptions and as quoted evidence. Scoliosis and short stature are recounted from the row cells instead of the row totals - 3 of 22 each, against category totals of 7/22 and 8/22 - and both move FREQUENT to OCCASIONAL. I counted those cells independently before changing them, and they sum correctly against the row totals (scoliosis 3 + other musculoskeletal 4 = 7; short stature 3 + small size 4 + low weight 1 = 8). Ten bands remain, all one-to-one or cell-counted; the three-case rule is now written into the entry notes. Arrhythmia gains OCCASIONAL from the paper's own 3/22 prose figure. The other two items were both the same false-absence failure as round 1's, which makes three in this entry's history. The surveillance entry said the source gave no screening interval. It gives three - annual echocardiogram, lifelong annual EKG with 24-hour Holter, baseline total-body MRA repeated at least every two years - in the same paragraph as a sentence the entry was already quoting. Stated and cited now. And the `Arterial aneurysm` note claimed HPO's aneurysm terms were all vessel-mismatched, citing `runoak -i ols:hp search 'l~aneurysm'`; re-running that exact query returns `HP:0034179` Vertebral artery aneurysm, an exact match for one of the three vessels in Table 2. That vessel now has its own phenotype, wired from Cardiac and Vascular Wall Vulnerability, and the note is rewritten per vessel: `HP:0034325` Common carotid artery aneurysm is declined because the source says only "Carotid Artery Aneurysm" and separately reports an internal carotid lesion, and no posterior cerebral artery aneurysm term exists (`HP:0031773` is the posterior communicating artery; `HP:0012495` is stenosis, not aneurysm). The pattern across all three is worth recording rather than just fixing: each was a sentence asserting that a source or an ontology lacked something, written without running the check it implied, and each was caught by a reviewer running it. The entry now carries no negative-existence claim whose query has not been executed in the same pass. Suggestion declined with a reason: a separate aortic-dilation phenotype. `runoak -i ols:hp search 'l~aortic dilatation'` returns nothing, and `HP:0004942` Aortic aneurysm would assert an aneurysm where Table 2 reports dilation. Recorded in the coarctation description. Re-validated after round 2: just validate 84 snippets / 89 titles / 0 issues; validate-disorders passed; validate-terms passed; check-entity-refs, check-causal-targets, check-duplicate-keys clean; list-disconnected-phenotypes 34/34 connected; 52 edges over 49 nodes with no orphan targets. Round 2 follow-up: CI failure I had missed. The round-2 push left `test (3.13)` red and I reported the PR as clean anyway, having queried only the review decision and mergeability. `mergeable` means there is no merge conflict, not that the checks pass, and the gate that failed was one of the eleven of CI's twenty-five whole-repo gates I had not run. The failure was this entry's, not inherited. `check-gene-activity-grounding` is a ratchet: a gene wired into the pathograph must land on a node carrying a molecular function, so that the graph states what the protein can no longer do and not only what the cell can no longer do. The `Reduced MED12 Dosage in the Mediator Kinase Module` node carried `biological_processes:` GO:0006366 and no `molecular_functions:`, which is exactly the shape the gate exists to catch - the node's own evidence snippet already said MED12 "interacts with chromatin and transcription factors to modulate chromatin architecture and transcriptional activity", and its explanation already called that the molecular function lost. Only the term was missing. Bound GO:0003712 transcription coregulator activity with modifier DECREASED, not its child GO:0003713 transcription coactivator activity: the CDK8 kinase module has activating and repressive roles in transcription, so the coactivator term would assert a direction the module does not uniformly have. MED12 is the module's scaffold and has no catalytic activity of its own, so the coregulator term is the protein-level function that reduced dosage lowers. Verified causal rather than assumed, because the local and CI readings of this gate differ sharply. Run without `--against-ref`, it reports 400 findings and pristine main fails it too, which looks like inherited breakage; run as CI runs it, against the base, the committed baseline grandfathers 3153 genes and only additions count. Without the fix, `--against-ref origin/main` reports exactly one new finding, this entry's MED12. With it, the gate passes. A `Cerebral_Amyloid_Angiopathy: APOE` finding seen in between was an artifact of comparing a branch whose base predated PR 13574 and disappeared on rebasing. All twenty-five of CI's whole-repo gates were then run rather than a selected subset: 25 pass, 0 fail. The subset is what let this through, and the ones omitted included both this gate and check-reference-titles.

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 43 citations 2026-10-09T15:53:10.400855

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Hardikar Syndrome
MONDO ID: MONDO:0012997 (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Hardikar Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Hardikar syndrome: disease-characteristics research report

Scope and evidence standard. Hardikar syndrome is exceptionally rare. Most disease-specific knowledge comes from individual clinical reports and a small molecularly characterized series, not population registries or electronic-health-record cohorts. The principal molecular study is Li and colleagues, published online in 2020 and in Genetics in Medicine in April 2021, PMID 33244166. A 2026 case report and literature review provides a more recent synthesis but includes a patient whose variant remains of uncertain significance. The 2024 article by Strong and colleagues, “Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome” (DOI:10.1016/j.gim.2024.101222), was identified bibliographically but its primary text could not be examined here; no experimental results are attributed to it below. (li2021denovolossoffunction pages 1-2, kahy2026anovelintronic pages 2-5, kahy2026anovelintronic pages 1-2)

1. Disease information

Hardikar syndrome is a congenital, multisystem Mendelian disorder classically combining orofacial clefting, pigmentary retinal abnormalities, hepatobiliary disease, intestinal malrotation, and urinary-tract anomalies. Neurodevelopment is often relatively preserved, although that characterization should not be extended uncritically to every person with a MED12 variant. The identifying disease record is MONDO:0012997, indexed by Open Targets as “cholestasis-pigmentary retinopathy-cleft palate syndrome”; MIM 301068 denotes Hardikar syndrome, while MIM 300188 denotes its causal gene, MED12. Useful alternative names are Hardikar syndrome, MED12-related Hardikar syndrome, and cholestasis–pigmentary retinopathy–cleft palate syndrome. The disease-specific Orphanet, MeSH, and ICD-10/ICD-11 codes could not be verified from the available sources; they should not be inferred from broader cholestasis codes. (OpenTargets Search: Hardikar syndrome, poley2008hardikarsyndromenew pages 1-3, kahy2026anovelintronic pages 1-2)

The evidence is patient-derived, subsequently summarized at disease level. For context, a 2026 review assembled 33 individuals from 12 reports, added one DECIPHER record and its own case, and analyzed 35 individuals; its two original, molecularly unconfirmed historical cases were excluded. These are literature-ascertained observations, not 35 independent prospective observations or a prevalence denominator. The review’s newly reported MED12 c.3868-5C>G case is clinically suggestive but not a genetically established Hardikar case, because the variant is a VUS. (kahy2026anovelintronic pages 2-5, kahy2026anovelintronic pages 1-2, kahy2026anovelintronic pages 16-18)

2. Etiology: causal, risk, protective, and environmental factors

The strongest disease-specific cause is a heterozygous, usually de novo, germline loss-of-function variant in X-linked MED12 in an affected female. The seven women investigated by Li and colleagues had nonsense or frameshift variants; exceptional mosaicism occurs. An X-linked dominant model with predominantly female recognition is supported, but whether all severe male loss-of-function genotypes are embryonically lethal is an inference, not an established penetrance measurement. MED12 missense variants can cause different MED12-related disorders—including FG, Lujan–Fryns, and Ohdo syndromes—and must not automatically be classified as Hardikar syndrome. (li2021denovolossoffunction pages 1-2, li2021denovolossoffunction pages 4-5, plassche2021med12related(neuro)developmentaldisorders pages 1-3, plassche2021med12related(neuro)developmentaldisorders pages 3-5)

No disease-specific environmental, infectious, dietary, lifestyle, occupational, or age-related initiating risk factor has been established. No protective allele, modifier gene, preventive exposure, or demonstrated gene–environment interaction has been established. Skewed X-chromosome inactivation is a plausible endogenous modifier of expression, but measurements in blood cannot establish inactivation patterns in liver or brain. KDM6A and KMT2D arise in a proposed transcriptional-network comparison with Kabuki syndrome; they are not validated Hardikar causal or modifier genes. (li2021denovolossoffunction pages 6-7, plassche2021med12related(neuro)developmentaldisorders pages 3-5)

3. Phenotypes and effects on functioning

The congenital structural phenotype is heterogeneous. Clefts can affect feeding and speech; intestinal malrotation can cause neonatal obstruction; urinary malformations can entail operations and recurrent infection. Cholestatic disease can produce jaundice, itching, nutritional impairment, growth failure, fibrosis, and occasionally hepatic failure. Retinal pigmentation need not imply early loss of vision: one reported child retained unaffected vision at age four. Bilateral sensorineural hearing loss requiring cochlear implants was reported in another child. Aortic coarctation or dilation and carotid/cerebral vascular abnormalities warrant attention; they are not present in every case. These statements describe observed cases, not established per-phenotype percentages. No syndrome-specific EQ-5D, SF-36, or PROMIS estimates were identified. (li2021denovolossoffunction pages 4-5, li2021denovolossoffunction pages 6-7, li2021denovolossoffunction pages 3-4, poley2008hardikarsyndromenew pages 1-3)

The following table gives phenotype-level HPO suggestions whose identifiers were explicitly reported in the retrieved clinical review. Onset and progression refer to observed cases, not a validated natural-history staging system. (kahy2026anovelintronic pages 5-6, kahy2026anovelintronic pages 2-5)

Observed phenotype	Evidence-informed onset/course and impact	Verified HPO ID	Frequency
Cleft lip and/or palate	Congenital, generally stable structural anomaly; may impair feeding, speech, hearing, and facial development and require staged surgical repair. (poley2008hardikarsyndromenew pages 1-3, li2021denovolossoffunction pages 3-4)	Cleft lip — HP:0410030; cleft palate — HP:0000175	Not reliably established; published cases only; characteristic but not universal.
Pigmentary retinopathy	Congenital or recognized in childhood; may remain stable with preserved vision, but longitudinal ophthalmic surveillance is warranted. (li2021denovolossoffunction pages 4-5, kahy2026anovelintronic pages 5-6)	HP:0000580	Not reliably established; published cases only; characteristic but not universal.
Cholestasis	Usually neonatal or infantile; severity ranges from persistent biochemical disease to progressive jaundice, pruritus, malnutrition, portal hypertension, and liver failure. (poley2008hardikarsyndromenew pages 1-3, kahy2026anovelintronic pages 15-16)	HP:0001396	Not reliably established; published cases only; recurrent core manifestation.
Biliary atresia	Congenital hepatobiliary malformation presenting in infancy; may cause severe obstructive liver disease and require surgical or transplant evaluation. (li2021denovolossoffunction pages 3-4, kahy2026anovelintronic pages 5-6)	HP:0005912	Not reliably established; published cases only; not universal.
Absent gallbladder	Congenital imaging or operative finding; may accompany severe biliary maldevelopment and cholestasis. The 2026 example carried a MED12 VUS and is supportive, not genetically definitive. (li2021denovolossoffunction pages 4-5, kahy2026anovelintronic pages 15-16)	HP:0011467	Not reliably established; published cases only; rare reported phenotype.
Intestinal malrotation	Congenital; may cause neonatal intestinal obstruction and require a Ladd procedure, with substantial acute surgical morbidity. (poley2008hardikarsyndromenew pages 1-3)	HP:0002566	Not reliably established; published cases only; characteristic but not universal.
Choledochal cyst	Congenital biliary anomaly; may coexist with progressive cholestasis and cirrhosis and has been identified during liver transplantation. (poley2008hardikarsyndromenew pages 3-4, poley2008hardikarsyndromenew pages 1-3)	HP:0100890	Not reliably established; published cases only; rare reported phenotype.
Hepatic fibrosis	Begins in infancy in severe cases and may progress to bridging fibrosis or cirrhosis, impairing growth and liver function. (poley2008hardikarsyndromenew pages 1-3, kahy2026anovelintronic pages 15-16)	HP:0001395	Not reliably established; published cases only; severity is variable.
Hepatic failure	Advanced outcome of progressive hepatobiliary disease; may necessitate liver transplantation and can be fatal without timely treatment. The 2026 VUS case must not be counted as molecularly confirmed. (poley2008hardikarsyndromenew pages 1-3, kahy2026anovelintronic pages 15-16)	HP:0001399	Not reliably established; published cases only; severe but not universal.
Hydronephrosis	Congenital urinary-tract manifestation; may reflect obstruction or ectopic/abnormal ureters and predispose to recurrent infection and renal procedures. (poley2008hardikarsyndromenew pages 3-4, kahy2026anovelintronic pages 5-6)	HP:0000126	Not reliably established; published cases only; not universal.
Vesicoureteral reflux	Congenital urinary dysfunction; increases urinary-tract infection risk and may require urologic surveillance or intervention. (li2021denovolossoffunction pages 6-7, kahy2026anovelintronic pages 5-6)	HP:0000076	Not reliably established; published cases only; not universal.
Hearing impairment	Congenital or childhood-onset, including severe bilateral sensorineural loss; may delay speech and require cochlear implantation. (li2021denovolossoffunction pages 3-4, kahy2026anovelintronic pages 5-6)	HP:0000365	Not reliably established; published cases only; rare reported phenotype.
Congenital diaphragmatic hernia	Prenatal or neonatal structural anomaly with potential respiratory compromise; represents an expanded phenotype rather than a defining feature. (kahy2026anovelintronic pages 1-2, kahy2026anovelintronic pages 5-6)	HP:0000776	Not reliably established; published cases only; rare and not universal.

Table: Compact phenotype annotations for Hardikar syndrome using HPO identifiers explicitly reported in the case-review literature. Frequencies remain unquantified because evidence comes from small, ascertainment-biased published cases; the 2026 MED12 VUS case is not treated as genetically confirmed.

Additional reported signs include preauricular pits/tags, ptosis, malformed external ears, failure to thrive, patent ductus arteriosus, ventricular septal defect, ectopic ureters, imperforate anus, vaginal atresia, and, in later phenotype summaries, diaphragmatic or pulmonary anomalies. Some affected individuals have normal cognition, but developmental impairment occurs across the wider MED12-related spectrum; disease attribution requires careful clinical and variant review. (li2021denovolossoffunction pages 6-7, li2021denovolossoffunction pages 3-4, poley2008hardikarsyndromenew pages 3-4, plassche2021med12related(neuro)developmentaldisorders pages 3-5, kahy2026anovelintronic pages 1-2)

4. Genetic and molecular information

Gene: MED12, mediator complex subunit 12, at Xq13.1; Open Targets lists Ensembl ENSG00000184634. The MED12 HGNC numeric identifier and an NCBI Gene identifier were not independently checked and are deliberately not assigned here. The 2021 clinically ascertained series reported the following seven variant descriptions, in its study numbering: c.322C>T, p.(Arg108*); c.2207_2210del, p.(Thr736Ilefs*43); c.2663dup, p.(Leu889Profs*11); c.4903_4906delinsCCAGCA, p.(Val1635Profs*61); c.5111G>A, p.(Trp1704*); c.5622C>A, p.(Tyr1874*); and c.6169C>T, p.(Gln2057*). These were described as pathogenic loss-of-function changes, predominantly de novo, with predicted nonsense-mediated decay; one early-stop finding was suspected to be mosaic in leukocytes. These are patient germline/developmental variants, not tumor-somatic driver claims. Exact population-allele frequencies for this set were not established from the retrieved evidence. (li2021denovolossoffunction pages 4-5, plassche2021med12related(neuro)developmentaldisorders pages 3-5)

For the seven-patient study, six individuals underwent X-inactivation assessment; five informative individuals showed skewing, with four particularly extreme ratios of 97:3–99:1. One assay was uninformative. These observations support a dosage-related hypothesis but do not prove which allele is expressed in each embryonic organ. An individual early-stop variant reportedly occurred in a mosaic patient; mosaic allele fraction and X-inactivation estimates must not be conflated. (li2021denovolossoffunction pages 4-5, li2021denovolossoffunction pages 5-6, li2021denovolossoffunction pages 6-7)

Important variant-classification counterexample: in the July 2026 report, trio follow-up identified de novo NM_005120.3:c.3868-5C>G, absent from the investigated population databases. Its predicted splice-acceptor effect had SpliceAI Δ = 0.60, but patient RNA and protein studies were unavailable; the authors retained VUS classification. It must not enter a knowledge base as a proven pathogenic splice allele or as measured MED12 loss of function. A de novo intragenic MED12 deletion was also identified in the review’s DECIPHER case; this supports considering copy-number analysis when sequence testing is unrevealing. No Hardikar-specific repeat expansion, mitochondrial defect, established epigenetic signature, or validated large recurrent chromosomal syndrome was identified. (kahy2026anovelintronic pages 2-5, kahy2026anovelintronic pages 15-16, kahy2026anovelintronic pages 16-18)

5. Environmental information

Hardikar syndrome is not an infection or intoxication and has no established causative environmental exposure. Prenatal imaging may be normal despite subsequent severe disease, as illustrated by the 2026 clinically suggestive case; that observation does not establish an environmental cause. Infectious complications may arise downstream of illness or treatment needs: recurrent urinary infections occurred in the 2008 case, while the 2026 child died with Pasteurella multocida sepsis during advanced liver disease. The latter patient’s MED12 variant remains a VUS; neither infection proves primary immunodeficiency due to Hardikar syndrome. No applicable causal pathogen NCBI Taxon or preventive chemical ChEBI identifier is justified. (poley2008hardikarsyndromenew pages 3-4, kahy2026anovelintronic pages 1-2, kahy2026anovelintronic pages 15-16)

6. Mechanism and pathophysiology

Ordered causal chain—evidence level shown at each step:

Pathogenic MED12 truncation or deletion leads to reduced functional MED12 dosage; transcript decay was predicted for the seven reported variants rather than quantified in every affected organ. [Human genetic evidence; tissue-level molecular consequence inferred.] (li2021denovolossoffunction pages 4-5, plassche2021med12related(neuro)developmentaldisorders pages 3-5)
Reduced MED12 leads to altered Mediator-dependent transcriptional regulation through the MED12–MED13–cyclin C–CDK8 kinase module and its connections to transcription factors and RNA polymerase II. [Established MED12 biology; the complete effect in Hardikar embryonic tissues remains inferred.] (plassche2021med12related(neuro)developmentaldisorders pages 1-3, plassche2021med12related(neuro)developmentaldisorders pages 3-5, rocha2010med12isessential pages 1-2)
Altered transcriptional regulation leads to disturbed developmental cell specification and organogenesis. Branch A: zebrafish med12 disruption impairs Sox32/sox17- and her5-associated endodermal programs, plausibly contributing to digestive/hepatobiliary malformations. Branch B: animal and cell experiments implicate SOX9, Wnt/β-catenin, and Wnt/planar-cell-polarity signaling, plausibly contributing to craniofacial, cardiac, and axial malformations. [Direct experimental evidence in models; organ-by-organ causal assignment in patients inferred.] (plassche2021med12related(neuro)developmentaldisorders pages 5-6, rocha2010med12isessential pages 1-2, shin2008multiplerolesfor pages 1-2)
Abnormal organ development leads to congenital clefts, malrotation, biliary-tract and urinary defects, retinal changes, and variable cardiovascular anomalies. The specific cellular lesion responsible for each individual human feature has not been demonstrated. [Human phenotype observed; connection to individual model pathways inferred.] (li2021denovolossoffunction pages 1-2, poley2008hardikarsyndromenew pages 1-3, li2021denovolossoffunction pages 3-4)
Biliary maldevelopment or impaired bile flow results in cholestasis, which in severe cases leads to ductular changes, fibrosis/cirrhosis, pruritus, malnutrition, portal hypertension, and possible liver failure. This last progression is directly supported by serial human clinical observations and biopsies; a universal course is not established. [Human clinical and pathology evidence.] (poley2008hardikarsyndromenew pages 1-3, poley2008hardikarsyndromenew pages 3-4, kahy2026anovelintronic pages 15-16)

What is established versus hypothesized. MED12 is a nuclear transcriptional regulator, not a proven missing bile-acid transporter, ion channel, or metabolic enzyme in this syndrome. In primary zebrafish experiments, shiri/med12 mutants showed liver/pancreas defects and altered endodermal her5 expression; med12 modulated Sox32-driven sox17 expression. Mouse Med12 hypomorphs had impaired canonical Wnt and Wnt/PCP signaling, neural-tube-closure and cardiac defects; null embryos failed gastrulation. Cellular studies summarized in the MED12 review implicated β-catenin, SOX9, REST, and Hedgehog pathway regulation, but effects of particular MED12 missense alleles in other disorders must not be assigned directly to Hardikar truncations. An early analogy to JAG1/Notch-related Alagille syndrome was explicitly speculation, not a demonstrated JAG1/Notch lesion in Hardikar syndrome. (plassche2021med12related(neuro)developmentaldisorders pages 5-6, poley2008hardikarsyndromenew pages 4-6, plassche2021med12related(neuro)developmentaldisorders pages 7-10, rocha2010med12isessential pages 1-2, shin2008multiplerolesfor pages 1-2)

Annotation suggestions, not validated disease-specific mechanism IDs: GO biological-process labels RNA polymerase II-mediated transcription, embryonic organ development, endoderm development, canonical Wnt signaling, planar-cell-polarity signaling, and bile-duct development; cellular-component label nucleus. Candidate CL cell labels are endodermal progenitor cell, cholangiocyte, hepatocyte, retinal pigment epithelial cell, and neural crest cell. These refer to implicated tissues or plausible embryonic precursors: there is no patient-cell atlas establishing that MED12 dysfunction selectively targets each listed cell type. No validated Hardikar-specific transcriptomic, proteomic, metabolomic, lipidomic, methylation, single-cell, spatial-omics, or CRISPR-screen signature was substantiated in the accessible primary clinical studies. The 2021 expert review proposed isogenic iNeuron modeling; a proposal is not a completed Hardikar functional assay. (plassche2021med12related(neuro)developmentaldisorders pages 1-3, plassche2021med12related(neuro)developmentaldisorders pages 3-5, plassche2021med12related(neuro)developmental pages 10-12, shin2008multiplerolesfor pages 1-2)

7. Anatomical structures affected

Primary sites: liver and biliary tree, gallbladder, gut/foregut, lip/palate, retina, and urinary/genital tract. Additional reported sites: heart and great vessels, carotid or cerebral vessels, external and inner ear, diaphragm, and lungs. The strongest demonstrated tissue pathology is portal fibrosis with bile-duct proliferation in the transplanted child and interlobular bile-duct paucity with portal fibrosis in the clinically suggestive 2026 VUS case; these findings are not identical and should not be collapsed into one obligatory lesion. Suggestions for UBERON labels, pending identifier validation, are liver, intrahepatic bile duct, extrahepatic bile duct, gallbladder, small intestine, lip, palate, retina, kidney, ureter, aorta, and diaphragm. The relevant MED12 subcellular annotation is nucleus/Mediator complex, not mitochondrion or lysosome. Clefting can be bilateral—the 2008 child had bilateral cleft lip and palate—but universal symmetry or laterality cannot be asserted. (poley2008hardikarsyndromenew pages 1-3, poley2008hardikarsyndromenew pages 4-6, plassche2021med12related(neuro)developmentaldisorders pages 3-5, kahy2026anovelintronic pages 15-16)

8. Temporal development

The anatomical defects arise prenatally and are recognized prenatally, neonatally, or in childhood depending on the feature and investigation. Hepatobiliary illness may first present as neonatal cholestasis; severe disease may progress over months or years, whereas many structural malformations are persistent but not intrinsically progressive after birth. In the 2008 child, biopsy showed bile-duct changes and fibrosis at approximately one month, cirrhosis was documented at 7.5 months, and liver transplant occurred at 24 months; she was active at eight years. A 2026 clinically suggestive child developed portal-hypertension complications and died at three years eight months before transplantation, but her MED12 VUS prevents treating this as a confirmed molecular-natural-history endpoint. There are no validated early/intermediate/late stages, progression rates, remission probabilities, or critical-period intervention trials. An embryonic vulnerability window of approximately 30–70 gestational days was proposed in 2008, not clinically validated. (poley2008hardikarsyndromenew pages 1-3, poley2008hardikarsyndromenew pages 3-4, poley2008hardikarsyndromenew pages 4-6, kahy2026anovelintronic pages 15-16)

9. Inheritance and population epidemiology

Inheritance: an X-linked, predominantly female phenotype associated with heterozygous MED12 loss-of-function variants; most molecularly characterized cases arose de novo, while reports of mosaicism and maternal transmission caution against assuming every family has zero recurrence risk. Penetrance, age-specific penetrance, reproductive fitness, carrier frequency, anticipation, founder alleles, ancestry-specific risks, consanguinity effects, and empirical germline-mosaic recurrence risk are unknown. Genetic counseling should consider parental testing and residual mosaicism rather than substitute a purported syndrome-specific percentage. (li2021denovolossoffunction pages 4-5, kahy2026anovelintronic pages 2-5, kahy2026anovelintronic pages 1-2)

Incidence and prevalence are unknown. Li and colleagues studied seven genetically characterized females in 2021; the 2026 review’s 35 analyzed entries reflect case compilation with molecular-certainty differences, not cases per 100,000. Its abstract states 34 previously reported cases before its new case. Published female predominance is not a measurable population male:female ratio. Cases reported from different families and locations do not establish geographic clustering, founder effects, or racial predisposition. (li2021denovolossoffunction pages 1-2, kahy2026anovelintronic pages 2-5, kahy2026anovelintronic pages 1-2)

10. Diagnostics

Clinical recognition and differential. Concurrent neonatal/infantile cholestasis, cleft lip/palate or unusual retinal findings, malrotation, urinary anomalies, and cardiovascular lesions should prompt assessment for Hardikar syndrome. Investigate clinically urgent alternatives including biliary atresia, Alagille syndrome (JAG1/NOTCH2-related), progressive familial intrahepatic cholestasis, and mitochondrial hepatopathies; CHARGE, 22q11.2 deletion, and Kabuki syndrome may overlap with aspects of the malformation pattern. No validated formal diagnostic score or unique biochemical biomarker was identified. (li2021denovolossoffunction pages 5-6, poley2008hardikarsyndromenew pages 4-6, kahy2026anovelintronic pages 16-18)

Tests actually used or supported by cases: conjugated bilirubin, liver enzymes and cholestasis evaluation; abdominal ultrasonography to examine liver, gallbladder, and bile ducts; specialist-directed imaging/assessment for intestinal malrotation and urinary abnormalities; echocardiography and vascular imaging; detailed ophthalmology and audiology. Liver biopsy has shown cholestasis, bile-duct pathology, and fibrosis but is not pathognomonic. One published case’s conjugated bilirubin increased from 1.4 mg/dL at 1.5 months to 14.0 mg/dL at 22 months, then fell to 0.2 mg/dL after transplantation. No Hardikar-specific EEG, EMG, ECG electrophysiological pattern or validated disease-specific LOINC assay was identified. (li2021denovolossoffunction pages 6-7, poley2008hardikarsyndromenew pages 1-3, poley2008hardikarsyndromenew pages 3-4, kahy2026anovelintronic pages 15-16)

Genetic approach: trio whole-exome sequencing (WES) or appropriately analyzed genome sequencing that covers MED12, followed by interpretation of variant class, phenotype, segregation, and possible mosaicism; ensure that the assay can assess splice-region changes and copy-number variation. Targeted MED12 sequencing may be reasonable for a highly characteristic phenotype or known familial allele. Chromosomal microarray is useful for alternative chromosomal diagnoses or detectable deletions but does not replace sequence analysis; a normal karyotype or FISH result does not exclude MED12 sequence variation. WGS may help where WES misses noncoding or structural changes, but disease-specific comparative diagnostic-yield data are unavailable. Transcript testing or a minigene assay could help resolve a plausible splice VUS; in-silico splice prediction is not equivalent to functional validation. No established disease-specific RNA-seq, proteomic, metabolomic, epigenomic, or liquid-biopsy clinical test was found. (poley2008hardikarsyndromenew pages 3-4, kahy2026anovelintronic pages 2-5, kahy2026anovelintronic pages 15-16, kahy2026anovelintronic pages 16-18)

11. Outcomes and prognosis

Prognosis is variable and insufficiently quantified: published reports include survival into school age after liver transplantation, progressive early cirrhosis, and a fatal unprovoked intracranial hemorrhage at age 21 in the 2021 series. The 2026 VUS case ended in fatal sepsis amid advanced liver disease, but is not a molecularly confirmed prognostic observation. There are no reliable five-/ten-year survival rates, average life expectancy, standardized disability rates, validated quality-of-life measures, or prognostic biomarkers. Clinical features with obvious potential prognostic importance include severity of cholestasis/portal hypertension and cardiovascular or cerebrovascular lesions; predictive performance has not been measured. Treatment of hepatic disease cannot be assumed to reverse extrahepatic congenital anomalies. (li2021denovolossoffunction pages 1-2, poley2008hardikarsyndromenew pages 1-3, poley2008hardikarsyndromenew pages 3-4, kahy2026anovelintronic pages 15-16)

12. Treatment and current real-world implementation

There is no demonstrated MED12-directed, disease-modifying pharmacotherapy. Care is multidisciplinary and lesion-directed; the NCIT labels below are suggested intervention mappings, not independently verified NCIT numeric codes. In one primary report, Ladd procedure treated malrotation, ureterostomies and later reconstructive urinary operations managed complex urogenital defects, gastrostomy supported feeding, and living-related-donor liver transplantation at two years treated end-stage liver disease. Jaundice resolved and growth improved after transplantation, but urinary infections recurred. Cleft repair and cochlear implantation were documented elsewhere in the clinical series. Candidate NCIT intervention labels include Liver Transplantation, Ladd Procedure, Cleft Lip Repair, Cleft Palate Repair, Gastrostomy, Ureterostomy, Cochlear Implantation, Echocardiography, Magnetic Resonance Angiography, and Genetic Counseling; verify exact vocabulary entries before database ingestion. (li2021denovolossoffunction pages 3-4, poley2008hardikarsyndromenew pages 1-3, poley2008hardikarsyndromenew pages 3-4)

Nutritional support and fat-soluble vitamins were given in the transplanted child; ursodeoxycholic acid did not improve that individual’s cholestasis, and this single response must not be represented as a controlled treatment comparison. Consider transplant assessment for severe progressive liver disease according to specialist practice. No Hardikar-specific efficacy percentage, comparative transplant rate, adverse-event rate, pharmacogenomic regimen, gene therapy, cell therapy, antisense/RNA therapy, targeted immunotherapy, or intervention trial/NCT identifier was identified by the disease-specific trial searches. This means not found in the searched registry, not proof that no unregistered intervention has ever occurred. Suggested chemical labels such as ursodeoxycholic acid and fat-soluble vitamins should receive ChEBI IDs only after independent vocabulary verification. (poley2008hardikarsyndromenew pages 1-3, poley2008hardikarsyndromenew pages 3-4)

13. Prevention, surveillance, and counseling

A de novo developmental disorder has no established lifestyle modification, vaccine, exposure avoidance, or primary pharmacological prophylaxis that prevents the underlying syndrome. Secondary prevention is timely recognition of organ complications and a molecular diagnosis where possible. Li and colleagues recommend coordinated ophthalmologic evaluation, echocardiography and serial cardiovascular assessment, carotid imaging and head/neck MRA, audiology, and hepatic, gastrointestinal, and genitourinary evaluation; their suggested serial schedules are case-series expert recommendations, not prospectively validated screening intervals. Manage nutrition and cholestasis and correct obstructive or vascular problems to reduce tertiary morbidity. Offer reproductive counseling and variant-specific familial testing when a pathogenic variant is confirmed; prenatal or preimplantation testing is technically conceivable for a known familial pathogenic allele, but there is no established population newborn or carrier-screening program for Hardikar syndrome. A VUS alone should not be treated as a definitive predictive familial test. (li2021denovolossoffunction pages 6-7, kahy2026anovelintronic pages 16-18)

14. Natural disease in other species and comparative biology

The human syndrome is documented in Homo sapiens, NCBI Taxon 9606. No naturally occurring veterinary Hardikar syndrome, affected breed/VBO designation, animal prevalence, animal-to-human transmission, or zoonotic potential was substantiated. Vertebrate conservation is supported instead by experimental Med12/med12 perturbations in mouse and zebrafish. Accordingly, a zebrafish embryo with disrupted med12 is a comparative developmental model, not a naturally occurring veterinary diagnosis. Species-level experimental phenotype similarities do not establish the complete human multi-organ syndrome in another species. (li2021denovolossoffunction pages 4-5, wang2006asubunitof pages 1-2, rocha2010med12isessential pages 1-2, shin2008multiplerolesfor pages 1-2)

15. Model organisms and research applications

Zebrafish, Danio rerio (NCBI Taxon 7955): the experimentally characterized shiri/med12 mutant has endodermal and liver/pancreas abnormalities linked to altered her5 and Sox32/sox17 regulation. The motionless/med12 mutant impairs selected monoaminergic neurons and cranial sensory ganglia; delivery of human MED12 RNA rescued aspects of the mutant phenotype. The kohtalo/med12 mutant reduces hindbrain boundary-cell formation and proliferation. These are distinct experimental alleles/phenotypes and should not be merged into a single engineered Hardikar organism. Mouse, Mus musculus (NCBI Taxon 10090): Med12 hypomorphic embryos showed defects in neural-tube closure, axis elongation, somitogenesis and heart formation, together with impaired Wnt and Wnt/PCP signaling; null embryos could not complete gastrulation. These models establish developmental roles but do not reproduce the full human retinal–biliary–cleft–urinary phenotype or faithfully mimic mosaic heterozygous human X inactivation. No validated animal knock-in of a specific human Hardikar allele was established in the accessible studies. Candidate model-resource entry points are ZFIN and MGI, subject to allele-specific record checks. (wang2006asubunitof pages 1-2, rocha2010med12isessential pages 1-2, hong2011thetranscriptionalmediator pages 1-2, shin2008multiplerolesfor pages 1-2)

Evidence quotations, dates, and primary-source links

Human clinical, Poley and Proud, 2008 (DOI:10.1002/ajmg.a.32266): abstract: “Hardikar syndrome (HS) is a disorder of multiple anomalies predominantly characterized by cleft lip/palate, liver and biliary tract disease, intestinal malrotation, obstructive uropathy, and retinopathy.” The same abstract describes “the need for liver transplantation.” (poley2008hardikarsyndromenew pages 1-3)
Human genetic, Li and colleagues, published online 2020; issue April 2021, PMID 33244166 (PubMed; DOI:10.1038/s41436-020-01031-7): the article’s title accurately summarizes its central finding, “De novo loss-of-function variants in X-linked MED12 are associated with Hardikar syndrome in females.” The reviewed evidence documents seven affected women and seven truncating variants; a longer verbatim abstract quotation could not be checked against directly readable publisher full text. (li2021denovolossoffunction pages 1-2, li2021denovolossoffunction pages 4-5)
Model-organism, Shin and colleagues, 2008 (DOI:10.1016/j.ydbio.2008.02.031): abstract: “shiri encodes Med12, a regulatory subunit of the transcriptional Mediator complex”; mutant embryos had liver and pancreatic developmental defects. (shin2008multiplerolesfor pages 1-2)
Model-organism, Rocha and colleagues, 2010 (DOI:10.1242/dev.053660): abstract: “the Wnt/planar cell polarity pathway is disrupted and ... canonical Wnt/β-catenin signaling is impaired” in Med12 hypomorphic mouse embryos. This is mouse evidence, not direct measurement in Hardikar patients. (rocha2010med12isessential pages 1-2)
Human clinical and literature synthesis, El Kahy and colleagues, published 9 July 2026 (DOI:10.3390/genes17070787): abstract: “The identified MED12 variant is classified as a variant of uncertain significance (VUS).” Its tabulated case compilation is informative but should not be used to imply population prevalence or to promote that variant to pathogenic. (kahy2026anovelintronic pages 2-5, kahy2026anovelintronic pages 1-2, kahy2026anovelintronic pages 16-18)

Knowledge-base confidence statement: The MED12–Hardikar association and congenital multisystem phenotype have strong human case-series support; the particular organ-specific transcriptional pathways remain largely cross-species mechanistic inference; exact phenotype frequencies, epidemiology, biomarker performance, and treatment response rates remain unestablished. (li2021denovolossoffunction pages 1-2, kahy2026anovelintronic pages 2-5, rocha2010med12isessential pages 1-2, kahy2026anovelintronic pages 1-2)

References

(li2021denovolossoffunction pages 1-2): Dong Li, Alanna Strong, Kaitlyn M. Shen, David Cassiman, Maria Van Dyck, Natalia Duarte Linhares, Eugenia Ribeiro Valadares, Tiancheng Wang, Sergio D.J. Pena, Jaak Jaeken, Samantha Vergano, Elaine Zackai, Anne Hing, Penny Chow, Arupa Ganguly, Tasja Scholz, Tatjana Bierhals, Deindl Philipp, Hakon Hakonarson, and Elizabeth Bhoj. De novo loss-of-function variants in x-linked med12 are associated with hardikar syndrome in females. Genetics in Medicine, 23:637-644, Apr 2021. URL: https://doi.org/10.1038/s41436-020-01031-7, doi:10.1038/s41436-020-01031-7. This article has 44 citations and is from a highest quality peer-reviewed journal.
(kahy2026anovelintronic pages 2-5): Nabil El Kahy, Adib Moukarzel, Nada Assaf, Riwa Chdid, Romy Moussallem, Nabiha Salem, and Alain Chebly. A novel intronic variant in med12 associated with a predominantly hepatobiliary phenotype suggestive of hardikar syndrome: a case report and literature review. Genes, 17:787, Jul 2026. URL: https://doi.org/10.3390/genes17070787, doi:10.3390/genes17070787. This article has 0 citations.
(kahy2026anovelintronic pages 1-2): Nabil El Kahy, Adib Moukarzel, Nada Assaf, Riwa Chdid, Romy Moussallem, Nabiha Salem, and Alain Chebly. A novel intronic variant in med12 associated with a predominantly hepatobiliary phenotype suggestive of hardikar syndrome: a case report and literature review. Genes, 17:787, Jul 2026. URL: https://doi.org/10.3390/genes17070787, doi:10.3390/genes17070787. This article has 0 citations.
(OpenTargets Search: Hardikar syndrome): Open Targets Query (Hardikar syndrome, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(poley2008hardikarsyndromenew pages 1-3): J. Rainer Poley and Virginia K. Proud. Hardikar syndrome: new features. American Journal of Medical Genetics Part A, 146A:2473-2479, Oct 2008. URL: https://doi.org/10.1002/ajmg.a.32266, doi:10.1002/ajmg.a.32266. This article has 16 citations.
(kahy2026anovelintronic pages 16-18): Nabil El Kahy, Adib Moukarzel, Nada Assaf, Riwa Chdid, Romy Moussallem, Nabiha Salem, and Alain Chebly. A novel intronic variant in med12 associated with a predominantly hepatobiliary phenotype suggestive of hardikar syndrome: a case report and literature review. Genes, 17:787, Jul 2026. URL: https://doi.org/10.3390/genes17070787, doi:10.3390/genes17070787. This article has 0 citations.
(li2021denovolossoffunction pages 4-5): Dong Li, Alanna Strong, Kaitlyn M. Shen, David Cassiman, Maria Van Dyck, Natalia Duarte Linhares, Eugenia Ribeiro Valadares, Tiancheng Wang, Sergio D.J. Pena, Jaak Jaeken, Samantha Vergano, Elaine Zackai, Anne Hing, Penny Chow, Arupa Ganguly, Tasja Scholz, Tatjana Bierhals, Deindl Philipp, Hakon Hakonarson, and Elizabeth Bhoj. De novo loss-of-function variants in x-linked med12 are associated with hardikar syndrome in females. Genetics in Medicine, 23:637-644, Apr 2021. URL: https://doi.org/10.1038/s41436-020-01031-7, doi:10.1038/s41436-020-01031-7. This article has 44 citations and is from a highest quality peer-reviewed journal.
(plassche2021med12related(neuro)developmentaldisorders pages 1-3): Stijn R. van de Plassche and Arjan P. M. de Brouwer. Med12-related (neuro)developmental disorders: a question of causality. Genes, 12 5:663, Apr 2021. URL: https://doi.org/10.3390/genes12050663, doi:10.3390/genes12050663. This article has 28 citations.
(plassche2021med12related(neuro)developmentaldisorders pages 3-5): Stijn R. van de Plassche and Arjan P. M. de Brouwer. Med12-related (neuro)developmental disorders: a question of causality. Genes, 12 5:663, Apr 2021. URL: https://doi.org/10.3390/genes12050663, doi:10.3390/genes12050663. This article has 28 citations.
(li2021denovolossoffunction pages 6-7): Dong Li, Alanna Strong, Kaitlyn M. Shen, David Cassiman, Maria Van Dyck, Natalia Duarte Linhares, Eugenia Ribeiro Valadares, Tiancheng Wang, Sergio D.J. Pena, Jaak Jaeken, Samantha Vergano, Elaine Zackai, Anne Hing, Penny Chow, Arupa Ganguly, Tasja Scholz, Tatjana Bierhals, Deindl Philipp, Hakon Hakonarson, and Elizabeth Bhoj. De novo loss-of-function variants in x-linked med12 are associated with hardikar syndrome in females. Genetics in Medicine, 23:637-644, Apr 2021. URL: https://doi.org/10.1038/s41436-020-01031-7, doi:10.1038/s41436-020-01031-7. This article has 44 citations and is from a highest quality peer-reviewed journal.
(li2021denovolossoffunction pages 3-4): Dong Li, Alanna Strong, Kaitlyn M. Shen, David Cassiman, Maria Van Dyck, Natalia Duarte Linhares, Eugenia Ribeiro Valadares, Tiancheng Wang, Sergio D.J. Pena, Jaak Jaeken, Samantha Vergano, Elaine Zackai, Anne Hing, Penny Chow, Arupa Ganguly, Tasja Scholz, Tatjana Bierhals, Deindl Philipp, Hakon Hakonarson, and Elizabeth Bhoj. De novo loss-of-function variants in x-linked med12 are associated with hardikar syndrome in females. Genetics in Medicine, 23:637-644, Apr 2021. URL: https://doi.org/10.1038/s41436-020-01031-7, doi:10.1038/s41436-020-01031-7. This article has 44 citations and is from a highest quality peer-reviewed journal.
(kahy2026anovelintronic pages 5-6): Nabil El Kahy, Adib Moukarzel, Nada Assaf, Riwa Chdid, Romy Moussallem, Nabiha Salem, and Alain Chebly. A novel intronic variant in med12 associated with a predominantly hepatobiliary phenotype suggestive of hardikar syndrome: a case report and literature review. Genes, 17:787, Jul 2026. URL: https://doi.org/10.3390/genes17070787, doi:10.3390/genes17070787. This article has 0 citations.
(kahy2026anovelintronic pages 15-16): Nabil El Kahy, Adib Moukarzel, Nada Assaf, Riwa Chdid, Romy Moussallem, Nabiha Salem, and Alain Chebly. A novel intronic variant in med12 associated with a predominantly hepatobiliary phenotype suggestive of hardikar syndrome: a case report and literature review. Genes, 17:787, Jul 2026. URL: https://doi.org/10.3390/genes17070787, doi:10.3390/genes17070787. This article has 0 citations.
(poley2008hardikarsyndromenew pages 3-4): J. Rainer Poley and Virginia K. Proud. Hardikar syndrome: new features. American Journal of Medical Genetics Part A, 146A:2473-2479, Oct 2008. URL: https://doi.org/10.1002/ajmg.a.32266, doi:10.1002/ajmg.a.32266. This article has 16 citations.
(li2021denovolossoffunction pages 5-6): Dong Li, Alanna Strong, Kaitlyn M. Shen, David Cassiman, Maria Van Dyck, Natalia Duarte Linhares, Eugenia Ribeiro Valadares, Tiancheng Wang, Sergio D.J. Pena, Jaak Jaeken, Samantha Vergano, Elaine Zackai, Anne Hing, Penny Chow, Arupa Ganguly, Tasja Scholz, Tatjana Bierhals, Deindl Philipp, Hakon Hakonarson, and Elizabeth Bhoj. De novo loss-of-function variants in x-linked med12 are associated with hardikar syndrome in females. Genetics in Medicine, 23:637-644, Apr 2021. URL: https://doi.org/10.1038/s41436-020-01031-7, doi:10.1038/s41436-020-01031-7. This article has 44 citations and is from a highest quality peer-reviewed journal.
(rocha2010med12isessential pages 1-2): Pedro P. Rocha, Manuela Scholze, Wilfrid Bleiß, and Heinrich Schrewe. Med12 is essential for early mouse development and for canonical wnt and wnt/pcp signaling. Development, 137:2723-2731, Aug 2010. URL: https://doi.org/10.1242/dev.053660, doi:10.1242/dev.053660. This article has 205 citations and is from a domain leading peer-reviewed journal.
(plassche2021med12related(neuro)developmentaldisorders pages 5-6): Stijn R. van de Plassche and Arjan P. M. de Brouwer. Med12-related (neuro)developmental disorders: a question of causality. Genes, 12 5:663, Apr 2021. URL: https://doi.org/10.3390/genes12050663, doi:10.3390/genes12050663. This article has 28 citations.
(shin2008multiplerolesfor pages 1-2): Chong Hyun Shin, Won-Suk Chung, Sung-Kook Hong, Elke A. Ober, Heather Verkade, Holly A. Field, Jan Huisken, and Didier Y. R. Stainier. Multiple roles for med12 in vertebrate endoderm development. Developmental biology, 317 2:467-79, May 2008. URL: https://doi.org/10.1016/j.ydbio.2008.02.031, doi:10.1016/j.ydbio.2008.02.031. This article has 76 citations and is from a peer-reviewed journal.
(poley2008hardikarsyndromenew pages 4-6): J. Rainer Poley and Virginia K. Proud. Hardikar syndrome: new features. American Journal of Medical Genetics Part A, 146A:2473-2479, Oct 2008. URL: https://doi.org/10.1002/ajmg.a.32266, doi:10.1002/ajmg.a.32266. This article has 16 citations.
(plassche2021med12related(neuro)developmentaldisorders pages 7-10): Stijn R. van de Plassche and Arjan P. M. de Brouwer. Med12-related (neuro)developmental disorders: a question of causality. Genes, 12 5:663, Apr 2021. URL: https://doi.org/10.3390/genes12050663, doi:10.3390/genes12050663. This article has 28 citations.
(plassche2021med12related(neuro)developmental pages 10-12): S van de Plassche and A de Brouwer. Med12-related (neuro) developmental disorders: a question of causality. genes 2021, 12, 663. Unknown journal, 2021.
(wang2006asubunitof pages 1-2): Xiaoqun Wang, Nan Yang, Etsuko Uno, Robert G. Roeder, and Su Guo. A subunit of the mediator complex regulates vertebrate neuronal development. Proceedings of the National Academy of Sciences, 103:17284-17289, Nov 2006. URL: https://doi.org/10.1073/pnas.0605414103, doi:10.1073/pnas.0605414103. This article has 97 citations and is from a highest quality peer-reviewed journal.
(hong2011thetranscriptionalmediator pages 1-2): Sung-Kook Hong and Igor B. Dawid. The transcriptional mediator component med12 is required for hindbrain boundary formation. PLoS ONE, 6:e19076, Apr 2011. URL: https://doi.org/10.1371/journal.pone.0019076, doi:10.1371/journal.pone.0019076. This article has 19 citations and is from a peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.3.0.

Outcome	Count
References checked	10
Resolved	10
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	10
On topic	3
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	15
Resolved	15
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	0
Terms whose name was checked	1
Terms named correctly	0
Terms named as a different term	1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0012997 (2 mentions) - the report calls it "if available"; MONDO calls it cholestasis-pigmentary retinopathy-cleft palate syndrome

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Hardikar syndrome: disease-characteristics research report

1. Disease information

2. Etiology: causal, risk, protective, and environmental factors

3. Phenotypes and effects on functioning

4. Genetic and molecular information

5. Environmental information

6. Mechanism and pathophysiology

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population epidemiology

10. Diagnostics

11. Outcomes and prognosis

12. Treatment and current real-world implementation

13. Prevention, surveillance, and counseling

14. Natural disease in other species and comparative biology

15. Model organisms and research applications

Evidence quotations, dates, and primary-source links

Artifacts

Reference Validation

Term Validation

Terms the report names something else